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Abstract

ANALYSIS OF DIFFERENTIAL GENE EXPRESSION AND ALTERNATIVE
SPLICING IN THE LIVER AND GASTROINTESTINAL TRACT IN THE LACTATING
RAT
Rat exon microarrays were utilized to detect changes in mRNA expression and
alternative splicing in the liver, duodenum, jejunum, and ileum of the lactating rat when
compared to age-matched virgin controls. Analysis of data at the level of gene
expression revealed differential expression of genes involved in cholesterol biosynthesis
in each tissue examined, suggesting increased Sterol Response Element Binding
Protein activity. We also detected decreased mRNA from components of the T-cell
signaling pathway in the jejunum and ileum. We characterized expression of solute
carrier and adenosine triphosphate binding cassette proteins. In addition to
characterizing genes by pathway, we have also grouped genes based on their pattern
of expression to identify important genes. Amongst genes upregulated in all tissues
was Slc39a4, which is a critical transporter in the absorption of zinc in enterocytes.
Alternative splicing analysis detected a substantial amount of alternative splicing in the
ileum compared to other tissues. In addition, in the liver Abcg8, a protein that functions
as a heterodimer to export cholesterol in the bile, shows differential splicing in the liver,
but not in other tissues. We also detected differential expression of Ugt1a6 in the liver
based on usage of an alternative first exon, which is consistent with altered protein
levels observed previously. Differential splicing also appears to occur in Ace2 in the
ileum, which could have consequences on the renin-angiotensin pathway.
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Chapter 1

Physiology and Endocrinology of Lactating Animals

Introduction

Lactation is a time of increased energy demand, as lactating mothers must
provide nutrients for both themselves and their offspring. In rats, who have large
litters, energy demand is increased four to five fold, while food intake increases
two to three fold [1-3]. Several changes in hormone levels occur to stimulate the
physiologic changes that take place during lactation. Prolactin (Prl) is critical in
the development of the mammary gland and stimulates milk secretion [4-7], and
its levels are increased in lactation. Thyroid hormone, leptin, and insulin serum
levels are all decreased, possibly to maintain energy balance within the lactating
animal by decreasing its energy expenditure. Amongst changes seen in lactating
rats are increased liver size [8] , growth of the small intestine [1], increased
cholesterol synthesis [9], and increased hydrophobicity and size of the bile acid
pool [10]. Growth of visceral tissue and improved cholesterol synthesis are also
observed in bovines [11, 12].

In this study, we analyzed the liver, duodenum, jejunum, and ileum of lactating
dams and compared these tissues against the same tissues in virgin controls.
1

The liver is the primary site of drug metabolism, and is also responsible for the
production of the various components of bile, which is important for lipid
absorption and the absorption of lipid soluble vitamins. The small intestine is
divided into three parts, the duodenum, jejunum, and ileum. The three parts
have different physiologic properties, and therefore were analyzed as three
different tissues. The duodenum, jejunum, and ileum as whole tissues also
include many different cell types. The duodenum includes Brunner’s glands,
which are mucuous secretory cells, while the ileum contains lymph nodules
known as Peyer’s patches [13]. Gene expression of transporters differs between
parts of the small intestine. For example, Abcc3 expression increases
substantially in the ileum [14], while Abcc2 expression is high in the duodenum
and is lower in the ileum [15-17]. A review of the expression of Solute carrier
(Slc) and Adenosine triphosphate binding cassette (Abc) proteins in the parts of
the small intestine can be found in Oostendorp et al [15]. These transporters can
control oral availability of various drugs.
Thyroid Hormone in the Lactating Animal

Thyroid hormone comes in multiple forms, with 3,5,3′-L-triiodothyronine (T3) being
the form that is considered biologically active [18]. Serum concentrations of
thyroid hormone are decreased in lactating rats [19]. Thyroid hormone is
required for milk secretion [7, 20, 21], and serum thyroid levels are below optimal
for maximal secretion [7, 21]. 5’ Monodeiodinase activity is increased in the
mammary tissue, which allows for the mammary gland to locally produce active
2

thyroid hormone, permitting the mammary gland to meet energy demands, while
conserving energy in other tissues [22]. The decrease in serum thyroid levels is
likely to be in order to conserve energy, as thyroid hormone is strongly
associated with energy metabolism. The actions of the thyroid hormone are
divided into “genomic” effects and “non-genomic” effects. There are multiple
forms of the thyroid receptor, which mediates the genomic effects of thyroid
hormone, and are produced by two genes, Thra and Thrb. In the liver and small
intestine, Thrb is the dominant form of the receptor [23]. Microarray technology
has been used to characterize how thyroid hormone influences gene expression
in cultured human fibroblasts [24], mouse brain [25], mouse liver [26-29], mouse
osteoblasts [30], and rat liver [31]. Among genes regulated in human fibroblasts
in response to T3 treatment is Kruppel Like Factor 9 (KLF9, also known as BTE
binding protein or BTEB1). Knockout of Klf9 in mice results in shorter intestinal
villi [32]. However, Klf9 is a transcriptional repressor and may also be involved in
inhibiting growth [33]. In addition, thyroid hormone is associated with
mitochondriogenesis [18]. Mitochondria are the major site of energy production
within a cell, and increasing the number of mitochondria aids in a cell’s ability to
produce energy. Truncated variations of isoform one of Thra and isoform one of
Thrb (TRα1 and TRβ1), have been shown to be specifically imported into
mitochondria, suggesting a mechanism for thyroid hormone to control
mitochondrial gene expression [34-36].

3

Nongenomic interactions of T3 are created through interactions with various
proteins. One pathway that is influenced by a direct protein interaction is the
PI3K/AKT pathway. T3 interacts directly with PI3K, which leads to
phosphorylation of AKT [37, 38]. The PI3Ks are a group of lipid kinases that are
subdivided into three classes based on sequence homology [39]. These
enzymes catalyze the conversion of phosphatidyl inositol (4,5) bisphosphate
(PIP2) into phosphatidyl inositol (3,4,5) triphosphate (PIP3) [40]. PIP3 can then
be converted back into PIP2 by phosphorylates phosphatase and tensin homolog
(PTEN), or PIP3 can phosphorylate the kinase 3'-Phosphoinositide-dependent
protein kinase 1 (PDK1) [39, 40]. PDK1 in turn phosphorylates the protein
product of v-akt murine thymoma viral oncogene homolog (AKT) [39, 41]. AKT in
turn controls a large number of cellular responses, including phosphorylating the
forkhead box transcription factors (FOXOs) and the mechanistic target of
rapamycin (mTOR) when it is part of mTOR complex 1 (mTORC1) [41, 42]. Both
of these processes control the ability of the cell to mobilize energy, the former by
deactivating transcription factors, and the latter by inhibiting the ability of
eukaryotic initiation factor 4E binding protein 1 (4EBP1) to bind to and inhibit
eukaryotic initiation factor 4E. Decreased 4EBP1 binding allows for additional
protein translation. The FOXO transcription factors control the expression of
phophoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6P),
two of the key enzymes for gluconeogenesis [43, 44].

Leptin and insulin in the Lactating Animal
4

Leptin is a cytokine secreted by adipose tissue and aids in regulating dietary
intake by acting on leptin receptors in the hypothalamus [45]. In general, high
leptin levels inhibit dietary intake. During lactation, leptin levels are low,
encouraging nutrient uptake through increased feeding [19]. Reducing leptin
activity reduces Adenosine Monophosphate Activated Kinase (AMPK) activity,
decreasing β-oxidation. AMPK is a major energy sensor for cells and plays a
major role in control of several metabolic pathways, including downregulating
gluconeogenesis in the liver, decreasing cholesterol synthesis by
phosphorylating 3-Hydroxy-3-methylglutaryl Coenzyme A reductase (Hmgcr),
controlling glucose uptake in muscle by upregulating Glut4, and improving fatty
acid oxidation and decreasing fatty acid biosynthesis by inhibiting acetyl-CoA
carboxylase (Acc), the rate limiting step of fatty acid synthesis [46, 47]. AMPK is
an enzyme composed of a combination of three subunits [48, 49]. The
completed enzyme functions as an energy sensor for the cell and is regulated by
the AMP/ATP ratio in the cell as well as multiple hormone signals [47]. Reduced
AMPK activity also encourages fatty acid synthesis, including stimulation of Acc,
[46], through decreased phosphorylation [47]. AMPK downregulates
gluconeogenesis by decreasing expression of PEPCK and G6P [47]. AMPK can
also suppress Pparγ coactivator 1α (Ppargc1α) by decreasing CRE-binding
protein-regulated transcription coactivator 2 (CRTC2) activity [47, 50].

AMPK

activity overlaps with several other signaling pathways, including those of insulin
and adiponectin . Decreased AMPK activity also encourages cholesterol
5

synthesis through decreased phosphorylation of 3-hydroxy-3-methylglutaryl-CoA
reductase, which is the rate limiting step of cholesterol synthesis [47]. AMPK
decreases ACC transcription through decreasing the activities of the transcription
factors SREBP-1c and carbohydrate responsive element binding protein
(ChREBP) [47]. Insulin, which also shows decreased levels in lactation,
decreases expression of the leptin receptor [51]. In cows, expression of the short
and long forms of hepatic leptin receptor increases 40% during the transition
from late pregnancy to early lactation [51]. Leptin mediates many of its
downstream signaling through JAK2/STAT3 activation [52].

Prolactin in the Lactating Animal

Prolactin is a hormone secreted from lactotrophic cells in the pituitary gland [53,
54], and is also secreted from the mammary epithelium, placenta, brain, and
immune system [53]. It is associated with mammary gland development and milk
secretion. It is closely related to growth hormone and placental lactogen, which
are believed to all have been derived from a common ancestral gene [54, 55].
Prl and placental lactogen bind to the prolactin receptor (Prlr), which has a long
form, an intermediate form, and a short form in the rat [54, 56], while growth
hormone has its own receptor [4]. Homodimerization of the Prlr in turn triggers a
JAK2/STAT5 signaling cascade, which is considered the canonical mechanism
for Prl signaling [4, 54]. Two JAK2 proteins phosphorylate each other and the
activated JAK2 proteins in turn phosphorylate STAT5a. STAT5a dimerizes and
6

transports to the nucleus, where it functions as a transcription factor and
regulates transcription

Hormones that have altered serum levels in lactation influence alternative
splicing

The decrease in insulin and leptin levels and the increase in Prl signaling during
lactation may lead to changes in pathways that ultimately control alternative
splicing of genes. All three of these hormones lead to downstream PI3K
signaling through different receptors [52, 57-61]. PI3k signaling in turn can lead
to downstream phosphorylation of several serine-arginine (SR) proteins. SR
proteins control splicing events through their interactions with RNA, allowing
recruitment of the ribonuclear proteins that perform the splicing reaction [62-64].
SR proteins require phosphorylation to recognize the potential splice site, and
dephosphorylation for the splicing reaction to be catalyzed [62, 65, 66]. Insulin
signaling can trigger differential splicing of protein kinase C β II through the PI3K
pathway and ultimately through differential phosphorylation of SRp40, a member
of the SR family of proteins that are often involved in the regulation of alternative
splicing [67]. Likewise, Prlr activation leads to differential splicing of neuronal
nitric oxide synthase (nNOS) in the rat anterior pituitary cell line GH 3 [68].
Consequently, differential alternative splicing through differential phosphorylation
of SR proteins downstream of PI3k signaling seems likely in lactating animals.

7

Energy Demands of Lactating animals

During lactation, many species are in negative energy balance [69]. Maintaining
a negative energy balance can produce a state where the animal is conserving
energy. Both thyroid and insulin, hormones that encourage energy expenditure,
have decreased serum levels in lactation, which is consistent with an energypoor state [3, 19, 70]. This negative energy balance has been proposed to be
causative of the hypoleptinemia seen in lactation [69] and is proposed to be
responsible for the increase in food intake during lactation [69]. However, this
explanation does not fully account for changes in food intake or in leptin levels.
In addition to energy demands, the suckling response has an influence on the
diurnal regulation of serum leptin levels [69]. Also, although leptin levels may be
reduced to compensate for negative energy balance, dietary intake does not
increase sufficiently to offset negative energy balance, as treatment of lactating
rats with exogenous leptin only decreases their dietary intake by 20% [3, 69].
Increased dietary consumption is associated with increased liver and intestinal
growth during lactation. In ruminants, several studies indicate an increase in liver
and intestinal growth corresponding to increased caloric uptake. Prl was initially
believed to be responsible for gut hypertrophy [71], as treatment with
bromocriptine, a drug that blocks Prl release, decreases small intestinal growth.
However, a later study directly investigating Prl showed that increased prolactin
levels are insufficient for intestinal hypertrophy [72].

8

Zinc absorption in lactating animals

Zinc (Zn+2) absorption is improved during lactation in both women [73-75] and
rats [76]. Duodenums from lactating rats display an increased uptake of 65Zn.
Duodenal zinc absorption increases throughout pregnancy and lactation and
returns to normal levels after weaning [76]. Zinc is an essential micronutrient
involved in bone formation, with calcium, phosphorus and magnesium being the
others [75]. In humans, zinc is the only one of these nutrients to continue to have
an increased absorption rate after birth [75], although evidence exists for Prl
improving intestinal absorption of calcium in the duodenum [77]. In lactating rats,
Prl increases the duodenum’s ability to uptake calcium through increased
expression of multiple transporters, including transient receptor potential vanilloid
family members five and six (Trpv5 and Trpv6) [77].

The Slc39 proteins are metal transporters. Of these, Slc39a4 has been
described as the primary transporter for intestinal uptake of zinc, and failure to
produce a functional form of this protein in humans leads to a disease state
known as acrodermatitis enteropathica [78]. There is an alternative mechanism
for zinc uptake. Although this mechanism is not well understood, the primary
method for treatment of acrodermatitis enteropathica is a high zinc diet. Because
lactating animals have improved zinc absorption, one of these mechanisms may
be improved in the lactating dam. Mechanisms controlling expression of Slc39a4
are poorly understood, but another zinc transporter in the same family, Slc39a1,
9

is upregulated in response to Prl treatment in prostrate-derived cancer cell lines
[78, 79].

Changes in the bile acid pool in lactating dams

The hepatocyte produces bile acids, which function in the intestine to solubilize
cholesterol and other lipids and facilitate their absorption. The bile acid pool size
and its hydrophobicity are increased in lactation. During a time course study
over days of lactation, a statistically significant increase in the bile acid pool size
is first noticed on day 10 of lactation [10]. A shift in the diurnal rhythm regulating
Cyp7a1, the rate limiting step of bile acid synthesis, and a significant increase in
Cyp7a1 transcription occurs at 16 h when compared against age matched virgin
controls. No such increase was detected in Cyp27a1, suggesting that the
primary mechanism for increased bile acid pool size is an increase in Cyp7a1
activity. The increase in transcription occurs alongside increased recruitment of
LXRα to the Cyp7a1 promoter, possibly through increased availability of LXR
substrate in the form of cholesterol [80]. Decreased repression of Cyp7a1
transcription plays a role in Cyp7a1 upregulation during lactation. Expression of
Fibroblast growth factor 15 (Fgf15) is downregulated in the ileum in lactation,
leading to decreased extracellular signal related kinase 1 and 2 (Erk1/2)
phosphorylation, as shown by the 88% decrease in phosphorylated Erk1/2 in the
liver of lactating rats [80].Coupled with the knowledge that in primary human
hepatocytes, FGF19, the homolog of Fgf15, inhibits CYP7a1 through the ERK1/2
10

pathway [81], these data provide a likely mechanism by which Cyp7a1
expression is increased in the liver of the lactating dam.

Changes in bile acid transport in lactating dams

In addition to the increased production of bile acids, expression of the bile acid
transporters Abcb11(Bsep), Slc10a2 (Asbt), and Slc10a1 (Ntcp), is also
upregulated. Bile acids are synthesized in the liver, exported into bile through
Abcb11, taken into the enterocyte by Asbt, transported into the portal circulation
by Ostα/β, and then taken back up in the hepatocyte by Ntcp. Abcb11and Ntcp
show a significantly increased level of protein relative to virgin controls on day 2
post partum as a response to Prl, as shown by treating rats with Prl and
measuring resulting Ntcp and Abcb11 levels [82]. The increase in Ntcp mRNA
and protein can be directly linked to increased JAK/STAT5 signaling at a Stat5
response element at -1237 to -758 bps in the Ntcp promoter and is mediated by
the long form of the Prlr [83]. Ntcp shows a two fold increase in protein and a 1.7
fold increase in Vmax for transport of taurocholate at day two post-partum, and
the increase in expression and protein is maintained for two weeks [82].
Regulation of Asbt appears to be posttranscriptional, as levels of Asbt mRNA are
not different between control and post-partum day 14-21 rats despite increased
Asbt protein expression [84]. Bile flow, which is generated by secretion of bile
salts, is essential for the biliary secretion of cholesterol and many xenobiotics,
and is increased in lactating rats [8, 85]. Bile flow, bile acid secretory rate, and
11

hepatic clearance of taurocholate in response to taurocholate infusion was
shown to be mediated by Prl [8].

Increased cholesterol synthesis in lactating animals

Cholesterol biosynthesis is increased in both the small intestine and the liver
during lactation. This was initially shown by an increase in incorporation of
tritiated water into newly synthesized cholesterol [9]. At day 14 postpartum, a
significant increase in cholesterol synthesis was detected per total organ in both
the small intestine and liver in lactating rats when compared against nonlacting
postpartum rats. 3-Hydroxy-3-methylglutaryl Coenzyme A reductase (Hmgcr)
shows increased activity in the liver of lactating rats sacrificed at 10:00 and 14:30
on day 10 post-partum compared to age-matched virgin controls [86]. Because
cholesterol biosynthetic enzymes are all sensitive to SREBP-2 activity [87, 88],
one possible mechanism is that SREBP-2 activity is increased during lactation in
these tissues. A similar trend has also been observed in the mammary gland
[89]. Increased amounts of cholesterol are essential in lactation, due in part
because it is needed for incorporation into the milk for growth and neural
development in the pups. However, cholesterol is also required for bile acid
synthesis, which is also increased in lactation. As indicated above, bile acids are
required for efficient intestinal absorption of cholesterol, lipid, and lipid-soluble
vitamins [90].
12

Cholesterol synthesis and lipogenesis are controlled by three transcription
factors, known as Srebps, which are made by two genes, the Srebfs. The Srebf1
gene codes for the transcription factors Srebp-1a and Srebp-1c, while Srebf2
codes for the protein Srebp-2. The three proteins differ in their ability to regulate
the processes of lipid synthesis and cholesterol biosynthesis, but there is overlap
between the target genes [87, 88]. Srebp-1a is more closely associated with
fatty acid synthesis, while Srebp-2 is more closely associated with cholesterol
biosynthesis, as shown in mice expressing dominant positive forms of the two
proteins [88]. The rate limiting steps of the two processes, Acetyl-CoA
carboxylase (Acaca or Acc) for fatty acid synthesis, and HMGCR for cholesterol
synthesis, are shown to be upregulated in mice expressing the dominant positive
form of Srebp-1a and Srebp-1c, as well as downregulated in Srebp chaperone
(Scap) knockout mice [87].

The Srebps share a common mechanism for activation [91]. Under conditions of
sufficient cholesterol concentrations, the protein product of insulin stimulated
gene (Insig) is bound to cholesterol, and keeps an Insig/Scap/Srebp complex
sequestered in the endoplasmic reticulum. When not bound to cholesterol, Insig
is degraded, freeing Scap to escort the Srebp to the Golgi where it is cleaved and
activated. The N-terminal of the Srebp protein can then travel to the nucleus,
where it functions as a transcription factor and stimulates the production of target

13

genes, including genes involved in fatty acid synthesis and/or genes involved in
cholesterol biosynthesis [91].

Microarray analyses of various models have identified several potential
downstream targets of Prl [53]. Amongst these targets is Srebf1, which codes for
the Srebp1a and Srebp1c proteins. The protein products of Srebf1 are strongly
associated with controlling fatty acid and cholesterol biosynthesis [87]. Srebf1 is
consistently downregulated in three different models of Prl deficiency, indicating
that Prl can control transcription of Srebf1 [53, 92]. Due to the increased need of
the lactating dam for both fatty acids and cholesterol, the activity of all three
Srebp proteins may be improved.

Changes in cholesterol and phospholipid transport into bile in lactation

Components of bile include cholesterol and phospholipids, in addition to bile
acids. While Abcb11 transports bile acids into bile, Abcg5 and Abcg8 function as
a heterodimer to transport cholesterol, and Abcb4 (Mdr2) transports
phospholipids into bile. mRNA expression of Abcg5 and Abcg8 in liver
decreases over 90% throughout lactation [93], and despite this loss of
Abcg5/Abcg8 in expression in liver there is no change in the cholesterol or
phospholipid concentration in bile during lactation. However, following infusion of
taurocholate, increased secretion of cholesterol was impaired relative to controls
14

indicating a decreased coupling of taurocholate and cholesterol excretion into
bile [93]. Western analysis does not detect Abcg8 protein in the livers of lactating
rats [93]. The decreased presence of function Abcg5/Abcg8 dimer uncouples
taurocholate and cholesterol transport into bile and could provide a mechanism
for retention of cholesterol while the lactating dam is in a physiologic state that
requires more cholesterol [93]

The Ugt1a Locus in Lactation

The UDP glucuronosyltransferase (Ugt) superfamily of proteins is responsible for
transferring glucuronic acid to their respective substrates in order to form water
soluble molecules that are often biologically inactive and are subsequently
excreted into urine or bile [93]. The Ugt1 gene associated with these proteins
generates several possible proteins based on usage of an alternative first exon
and common exons 2-5 [93]. In transgenic mice expressing the human form of
the UGT1A locus, UGT1A4 and UGT1A6 expression are both elevated during
lactation [93]. In rats, protein and mRNA levels of Ugt1a6 are increased in the
liver, and its expression is also increased by treatment of rats with Prl,
suggesting that Ugt1a6 expression is sensitive to Prl levels [94]. These data
provide the rationale for studying expression of the alternative exons in the rat
Ugt1a locus. The Affymetrix Rat Exon 1.0 ST array (Affymetrix, Santa Clara, CA)
provides probes that interrogate these exons, and consequently allow for
detection of differential expression of the various mRNAs produced by the Ugt1a
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locus. Substrates of Ugt1a6 include phenols such as acetaminophen, and
consequently Ugt1a6 is important in drug metabolism in the lactating animal [95].

Rationale

In light of the large number of physiologic changes that occur in lactating animals
relative to virgin animals of the same species, characterization of every
transporter, enzyme, hormone, and transcription factor that has altered
expression during lactation would be inefficient, time consuming, and expensive.
Characterization of the transcriptome of the lactating animal allows a better
understanding of the ability of lactating animals to absorb and metabolize
nutrients and respond to changes in hormone levels. Understanding the
transcriptome can in turn lead to hypotheses regarding mechanisms of how
lactating animals absorb key nutrients, synthesize important metabolites, and
respond to altered levels of hormones in serum. Here, we utilized the Affymetrix
Rat Exon 1.0ST exon chip to characterize mRNA expression and differential
alternative splicing in tissues from day 10, 16 h lactating rats compared to agematched virgin controls. Day 10, 16h lactating rats were chosen because this is
the first time point at which a statistically significant increase in expression and
activity of Cyp7a1, the rate limiting step of bile acid biosynthesis, is observed
[10]. The microarray analyses should support our previous results regarding
expression of key enzymes, such as Cyp7a1, in bile acid and cholesterol
synthesis as well as transporters important for their transport into bile [10, 93], in
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addition to providing insight into their mechanisms of regulation. Finally, new
information regarding expression and regulation of additional pathways important
for changes of biological importance in the lactating dam should be discovered.

© Antony Athippozhy 2011
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Chapter 2
Analysis of Microarray Data
Microarray Design
While technology now exists for high throughput analysis of large biological
datasets, biological systems are extremely complicated and require advanced
techniques to mine and interpret the data. For example, microarray technology
allows for the measurement of most RNAs within a given sample. Bioinformatics
is the field of study in which “information sciences” such as computer science
and statistics are utilized to interpret biological data.
Microarray technology is based on nucleotide hybridization methods.
Oligonucleotide probes are utilized to detect the presence of cDNA synthesized
from RNA samples and tagged with a fluorescent dye. Original microarrays
utilized probes designed for the 3’ ends of genes and were utilized for the
estimation of overall gene expression. Newer designs can contain probes
designed to span an entire transcript. These arrays also allow the estimation of
differential alternative splicing between different experimental conditions.
Affymetrix is a supplier of chips utilizing oligonucleotide probes synthesized in
situ on a glass plate. For simplicity’s sake, data analysis will be discussed with
respect to the Affymetrix platform, but many of the same concepts are applicable
to other platforms.
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Pooling
Microarray chips can be expensive when compared to the cost of individual
biological samples. Consequently, one method to circumvent the cost of a
microarray experiment is to combine mRNA/cDNA from several samples to
reduce the variance between individual chips. As more samples are pooled, the
mRNA/cDNA concentration for a given gene approaches the population average
for the new pooled sample, reducing the effect an individual rat would have on
the measurement of gene expression. Power calculations demonstrate that
increasing the number of samples pooled and loaded onto a chip can give similar
power to that obtained by running a larger number of arrays. In an experiment in
which p samples are mixed, the number of arrays needed to obtain a similar
power in the absence of pooling is approximately 1/p, assuming a large number
of samples [96]. Therefore, an experiment utilizing six chips, each containing
mRNA from five individual samples would be comparable in statistical power to
an experiment containing thirty individual samples.
Preanalysis Data Treatment
When fluorescence intensities are initially measured from the array, a number of
biases exist that are independent of the biological sources of variance [97]. For
example, a difference in lighting on individual chips would lead to a chip effect
that could influence interpretation of the results. Consequently, a number of preanalysis steps are required to convert the fluorescence intensities into data that
have biological relevance. These steps usually include a background correction
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step, a normalization step, and a transformation step, as described below. One
commonly used method for performing these tasks is the Robust Multichip
Averaging (RMA) method, although other techniques exist.
The first step in adjusting the data is background correction. Affymetrix originally
utilized intentionally mismatched probes at the thirteenth nucleotide in a 25mer
oligonucleotide probe to determine amounts of nonspecific binding. However,
this method was found to not be effective, as the measured intensity of the
mismatch probe was found to increase as the intensity of the perfect match
probe increased [98], suggesting that the mismatch probe had specific affinity for
the target sequence. One method to circumvent the usage of mismatch probes is
to assume that the background is based on random error, and calculate it from
the standard deviation of perfect match signals, as is done in RMA. The RMA
background correction assumes that the observed signal is produced as the sum
of the actual signal from the bound target and random error. The bound target
signal is assumed to be exponential and the error is assumed to be normally
distributed. A description of the normalization procedure can be found at
http://bmbolstad.com/misc/ComputeRMAFAQ/ComputeRMAFAQ.html.
Normalization is performed in order to make each chip comparable by removing
nonbiological effects and allows for measurements on separate chips to be
comparable to each other. The RMA algorithm utilizes quantile normalization
[99]. In this method, probe intensities are ranked for each chip. Then for each
rank (e.g., the highest, 50th highest, 100th highest, etc), the average across all
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chips is taken, and the corresponding values are all set to the average. This
forces the distribution of measurements on all chips to be equal [100].
The final steps toward getting the data into a workable format are 1) log2
transformation of the intensities allowing for the use of parametric statistical tests
by adjusting the distribution of the measurements, and 2) summarizing the
intensity values of individual probes into a single measurement for the
corresponding exon or gene. In RMA, Tukey’s median polish [99] is utilized to
summarize the data, but other methods such as Tukey’s biweight have also been
utilized [99].
Detection of Differential Gene Expression
Once the data between each individual microarray chip is comparable to data
from the other chips, a method of analysis needs to be chosen. Early microarray
experiments utilized a fold-change approach. The problem with this approach is
that it only compares the means of a given gene’s expression between two
groups, and not the variance within those measurements. Consequently, this
method does not allow for the calculation of the likelihood of a false positive.
Correcting for the likelihood of false positives within the experiment is discussed
in the “Multiple Testing in Microarray Data” section below.
Either a parametric or nonparametric approach can be chosen to identify
differentially expressed genes. The nonparametric approach makes no
assumptions about the distribution of the data, but at the loss of statistical power.
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The parametric approach requires that the data being tested be approximately
normally distributed. ANOVA and Kruskal-Wallis tests have been frequently
used in microarray datasets to detect differential gene expression.
We have studied a system in which lactating rats were compared against agematched virgin controls. We analyzed four tissues from each rat and pooled
RNA from the same tissue from four rats within the same physiologic state
(control or lactating). The pools of four rats were consistent between tissues. In
other words, if rats 1,2,3, and four composed pool one in the liver, the same four
rats would compose pool one in the duodenum, jejunum and ileum. This led to a
two-way, mixed models, repeated measures experimental design. Mixed models
approaches can be utilized when multiple samples are taken from the same
subject. In this case, the four tissues were all taken from the same sets of four
rats. This led to a design in which we had two fixed effects (tissue and
physiologic state) and one random effect (the subject variable, which in this case
is a set of four rats.) A mixed model is comparable to the corresponding linear
model, except that the model is now expanded so that each term contains a
matrix that accounts for the individual samples. Accounting for the presence of
the individual subjects also generates a second error term that accounts for
differences between unique samples and is based on the covariance matrix.
This means that a method for approximating the covariance matrix must be
applied. One method, known as compound symmetry, was to assume that all
covariances are equal.
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Multiple Testing in Microarray Data
Due to the large size of a microarray data set, multiple tests have been
performed in order to detect changes in gene expression. Two types of error
could be made, rejecting the null hypothesis (measurements are made from the
same distribution) when it should not have been rejected (Type I error, or a false
positive) and failing to reject the null hypothesis when it should have been (Type
II error, or a false negative). Although the probability of any given test producing
a type I error (alpha) is small, the probability that a false positive exists within the
entire data set, (the family-wise error rate) may still be very high. There are
several ways to correct for this. One of the earliest methods to correct for
multiple testing was the Bonferroni procedure [101]. However, this test is
extremely conservative, and leads to a very small list of differentially expressed
genes. A second approach is to correct for the family-wise error rate (FWER)
[101]. This method attempts to control the probability that a false positive
appears anywhere in the dataset. However, because of the exploratory nature of
many microarray studies, this test is still overly conservative, as many
experimenters would be willing to accept the existence of a few false positives
within the dataset. The false discovery rate (FDR) method attempts to fix the
ratio of false positives to total positives in a given dataset [102]. The BenjaminiHochberg procedure for calculating false discovery rates lets p 1 ,p 2 ,…p m be the
rank ordered p-values, where m is the total number of tests. [All hypotheses
where p i <iα/m are rejected [102], where i is the i’th ranked p value and α is the
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cutoff value for the FDR.] A common cutoff for the FDR is 0.05, but even this
may be too conservative for some studies. An alternative to fixing the FDR is to
fix a set p-value cutoff, and calculate what the FDR or proportion of false
positives (PFP) is at the given p-value. The challenge in choosing an appropriate
cutoff is that as the probability of a type I error decreases, the probability of a
type II error increases. Note that although the Benjamini-Hochberg [102] method
was the first described to control the FDR, other methods exist [101]. Here we
set the p value cutoff threshold and calculated the PFP.
Detection of Trends and Pathways in A List of Differentially Expressed
Genes
Once a list of differentially expressed genes has been generated, the
experimenter must determine which genes are of particular interest. Given a list
of the differentially expressed genes and a database that organizes these genes
into various categories (for example, organizing genes by pathway or function), a
test can be performed to identify whether a given category is overrepresented in
this list of genes. Several methods exist for detecting overrepresented groups of
differentially-expressed genes [103]. One method is to utilize a right-tailed
Fisher’s Exact test to identify the probability that a number equal to or higher than
the number of genes actually detected within a group would appear by chance
[104]. This method is utilized by DAVID [104, 105] and Ingenuity Pathways
Analysis (IPA) (Ingenuity Systems, www.ingenuity.com). Because a test is
performed for each category of genes, multiple testing is an issue, and a multiple
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testing procedure such as the FDR can be applied to correct for the possibility of
a high number of type I errors [104].
Analysis of differential alternative splicing provides many additional challenges.
On an Affymetrix exon array, the probes on the array are divided into probesets,
which correspond to regions of a transcript. For the purposes of analysis, the
probesets are each treated as independent exons, although large exons are
often assigned multiple probesets. Based on the source of information Affymetrix
utilized to design the probes, Affymetrix assigns each probeset to a “confidence
level”. “Core” probesets are regions that are drawn from a curated database
such as Refseq. “Extended” probesets are derived from expressed sequence
tag (EST) databases. “Full” probesets are derived from software predictions.
There are 92,354 probesets at the Core confidence level on the Affymetrix Rat
Exon 1.0 ST array. Consequently, a large number of exons could test positive by
chance, and multiple testing is problematic. The Benjamini-Hochberg approach
has been applied to address this issue [106], and is readily available in software
packages, but to our knowledge, the multiple testing issue has not been
addressed specifically for exon arrays.
Detection of Differential Alternative Splicing
After performing a data treatment algorithm such as RMA, data can be
summarized at both the probeset and transcript level. Summarizing data at the
probeset level permits analysis at the exon level. However, a large difference
between intensities of a given probeset is not sufficient for identifying
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differentially alternatively spliced transcripts. Although a specific probeset may
display differential expression, the transcript itself may be differentially
expressed. Consequently, determination for whether or not a specific treatment
triggers differences in alternative splicing must take into account differences in
mRNA expression.
Affymetrix arrays lack junction-specific probes, and therefore methods designed
for detecting alternative splicing using this information is invalid. Three of the
methods that do not take into account this information are Analysis of Splicing
Variance (ANOSVA) [107], Microarray Dectection of Alternative Splicing (MiDAS)
[97], and Finding Isoforms from Robust Multichip Analysis (FIRMA) [108].
Affymetrix proposed the MiDAS method as a means of detecting differential
alternative splicing between multiple groups. In this method, probeset intensities
are divided by transcript level intensity to create a gene-normalized intensity.
Then, a statistical test (an ANOVA, if done as originally proposed by Affymetrix)
is utilized to determine differences in gene-normalized intensities between
treatment groups. The first problem to address is that without adequate filtering,
every exon in the dataset is tested at least once for alternative splicing. This
leads to a very high number of statistical tests, and the problem of multiple
testing becomes substantial, especially if the treatment triggers a relatively small
number of changes in differential splicing when compared to the entire dataset.
The second is that the calculated transcript level intensity needs to be accurate,
because the algorithm is dependent on using the transcript level estimate to
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normalize all probesets within that transcript. This can be particularly
problematic in a gene that has a large number of splicing events, since the
transcript level measurement is summarized from the probeset level
measurements (even if in principle, the individual probes are treated separately
for the purposes of summarization.) Reports exist stating that the distribution of
p-values resulting from MiDAS are not normally distributed in the non-significant
range [109].
The ANOSVA method utilizes a linear model to determine if differences in
alternative splicing occur between groups. The model follows the form of
yijkl=μ+αi+βj+γij+error, where the error is normally distributed around mean zero
and random, μ is the baseline intensity, αi is the “exon effect”, βj is a “treatment
effect”, and γij is the interaction term between αi and βj. The interaction term
(treatment*exon) is utilized as a means of determining if a transcript is
differentially alternatively spliced between treatment groups [107]. A significant
interaction term is determined to be a positive test. This conclusion operates
under the assumption that if a probeset’s intensity is not the sum of random error,
the treatment effect, and the individual exon effect (which can also be considered
as a probe affinity term) then the difference must be caused by differential
alternative splicing. A significant interaction is graphically visible by plotting
intensities as a function of exon for all treatment groups. In the absence of an
interaction term, the intensities for each group will be parallel when plotted as a
function of the individual probesets (Figure 2.1). This can be seen in that the
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intensities of both control and lactation are parallel for Abcg5 in the ileum, but in
Ace2 there is a point where the two lines were not parallel, indicating possible
alternative splicing at that point. However, there are a number of situations
where events other than differential alternative splicing cause a significant
interaction effect. This will lead to false positives, and because the underlying
assumptions regarding what is defined as alternative splicing are violated, even a
transcript with a low interaction p-value may be a false positive under certain
circumstances. These circumstances are discussed below.
FIRMA is a method based on utilizing the RMA algorithm. The model
(PM ik )=c i +ρ k+Є ik , is utilized to calculate residuals for each individual probe,
where PM ik is the measured intensity from the probe, c i is the chip effect
(expression level), p k is the probe effect (or probe affinity), and Є ik is the random
error [108]. The median residual (the difference from the mean) divided by the
standard deviation is used as a score to identify exons that are differentially
spliced. Unfortunately, a good guideline for a significance cutoff based on
FIRMA scores has not been developed [108].
A number of events can occur that will lead to false positives. The first is the
absence of either a gene that is not expressed in a treatment group, or an exon
that is expressed in no treatment groups. Because the methods for detection are
based on the relative expression of a probeset relative to the gene, the absence
of a probeset in both groups or the absence of the gene in one group lead to
false assumptions in the algorithm. In order to filter out poorly expressed
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probesets, Affymetrix has developed the Detection Above Background Algorithm
(DABG) algorithm [110], as exon arrays do not have single nucleotide mismatch
probes. In this method, background probes of random sequences of the 26
possible GC contents for a 25-mer oligonucleotide sequences are measured.
These probes are used as a background for probes of the same GC content.
Probesets with a DABG p-value of less than 0.05 can be considered present at
above background levels, although making the threshold more stringent is
possible. No method for specifically determining the presence or absence of a
given gene has been developed, so genes have a presence/absence call based
on the exons within the same transcript [97].
Cross-hybridization can also be problematic. In the presence of crosshybridization, an increase in measured intensity will appear, and the
measurement may often be higher than constitutively expressed exons.
Affymetrix recommends eliminating measurements that appear at a much higher
or much lower intensity than other probesets in the gene. Removing highly
expressed probesets is not problematic, as the intensity appears higher than
other constitutively expressed exons. However, removing poorly expressed
exons is problematic, as it is difficult to tell whether poor expression is caused by
poor hybridization or by only a fraction of the transcripts in fact containing
sequences corresponding to the probeset of interest, in which case the exon
positive test is detecting differential alternative splicing.
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Another risk is if the probe sequences are annotated incorrectly. Affymetrix
assigns each probeset a “confidence level” based on the line of evidence utilized
to identify the transcript associated with the probes. Selecting to analyze genes
only at the “Core” confidence level reduces the chance of misassignment.
A final potential problem Affymetrix warns about is extremely low variance across
a specific probeset, since the low variance could be mediated by an event such
as the probe not hybridizing to the target sequence. Affymetrix does not
recommend a specific filter for identifying regions with excessively low variance,
but the possibility of an exon showing low variance for reasons independent of
alternative splicing should be taken into account.
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Figure 2.1: Genes that test negative (Abcg5 top) and positive (Angiotensin
converting enzyme 2, bottom) for alternative splicing in the ileum. Chromosome
position is plotted on the x-axis, chromosome number is listed on the left y-axis,
and probeset intensity is plotted on the right y-axis. Note that for the gene
(Abcg5) that tests negative, the exon intensities appear to be parallel between
control and lactating groups as a function of chromosome position, while this is
not true for the gene (Ace2) that tests positive. Along the top of each figure is the
gene and its corresponding refseq entry, with the boxes representing individual
exons. Both Abcg5 and Ace2 are annotated as being on the minus strand. In
order to show both strands, Partek draws genes on the minus strand with the 5’
end on the right and the 3’ end on the left.

© Antony Athippozhy 2011
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Chapter 3

Differential gene expression in liver and small intestine from lactating rats
compared to age-matched virgin controls detects increased mRNA of
cholesterol biosynthetic genes

Background

Lactation is a time of a four- to five-fold increased energy demand imposed by
the suckling young that requires a proportional adjustment in the ability of the
lactating dam to absorb nutrients and to synthesize critical biomolecules to meet
the dietary needs of both the offspring and the dam [1-3]. Lactating rats have a
two- to three-fold increase in food consumption (hyperphagia) [1-3], in part
through the decreased suppression of appetite accompanying decreased serum
leptin [19].

Diet and hyperphagia have been shown to influence the rate of cholesterol
synthesis, which is increased in the liver and small intestine in the lactating rat [9,
111]. Of these tissues, the liver is the primary contributor to serum levels of
cholesterol, and shows a quantitatively greater increase in the rate of cholesterol
synthesis during lactation [9]. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase
(Hmgcr), the enzyme catalyzing the rate-limiting step of cholesterol synthesis,
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shows significantly increased activity in the liver during lactation compared to
virgin and nonlactating control rats [86, 112]. Cholesterol synthetic and lipogenic
genes are regulated by transcription factors termed sterol regulatory element
binding proteins (Srebp); the activity of Srebp proteins is in turn regulated by the
Srebf chaperone (Scap) and the Insulin induced genes (Insig).

Circulating serum levels of several hormones that regulate metabolism are
decreased during lactation in the rat, including thyroid hormone, insulin and leptin
[19]. Such changes in hormone signaling and diet are likely to have large
influences on the activation of their corresponding pathways. Receptors for
leptin, thyroid hormone, and insulin are expressed in both the liver and small
intestine [23, 113-117], with liver being considered a major site of insulin
signaling [113] and thyroid receptor β (TRB, Thrb) being the dominant form of the
thyroid receptor in both tissues [23]. Leptin acts on the small intestine and
inhibits sugar uptake [115], and the liver is a major source of the soluble form of
the leptin receptor, particularly under conditions of negative energy balance
[116], as occurs in lactation [3]. Therefore, altered serum levels of these
hormones would be expected to influence mRNA expression of downstream
genes.

Our laboratory has been investigating the effects of lactation on the synthesis
and transport of bile acids in the liver and small intestine in the rat [10]. Bile
acids are synthesized in the liver from cholesterol, and are essential for the
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biliary excretion of cholesterol and for the efficient intestinal absorption of
cholesterol, lipid-soluble vitamins and lipids [90]. Bile acids are secreted into bile
by the Bile salt export pump (Bsep; Abcb11), taken up across the apical
membrane of the enterocyte in the terminal ileum by the Apical sodiumdependent bile acid transporter (Asbt; Slc10a2), effluxed into portal blood by the
Organic solute transporter heterodimer (Ostα/β), and then taken up in the
hepatocyte by the Sodium-dependent taurocholate co-transporting polypeptide
(Ntcp; Slc10a1) [118]. Expression of Ntcp, Bsep and Asbt are all increased in
lactation [82, 84], as is the size of the bile acid pool [10]. We recently
demonstrated that expression and activity of Cyp7a1, the enzyme catalyzing the
rate limiting step in the conversion of cholesterol to bile acids, is increased at
mid-lactation (day 10 – 14 postpartum) [10]. Further, this increase occurs at 16 h
(10 h of light on a 12 h/light dark cycle; 4 PM) and represents a shift in the diurnal
rhythm of Cyp7a1 expression, which is normally maximal in the dark cycle (i.e.,
22 h). Increased expression of Cyp7a1 is apparently due to decreased
expression of Fibroblast Growth Factor 15 (Fgf15) in the ileum, resulting in
decreased FGF15 signaling via Fibroblast Growth Factor Receptor 4 (Fgfr4) and
Erk1/2 in liver and decreased repression of Cyp7a1 transcription [119].

In order to identify further changes in expression of genes important in the
regulation of bile acid and cholesterol synthesis, as well as other genes important
in meeting nutritional demands and physiological changes of the lactating rat, we
carried out a microarray experiment in the liver and small intestine of the lactating
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dam at 16 h on days 10 -11 postpartum and compared these to gene expression
in female virgin control rats.
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RESULTS
Detection of differentially expressed genes

A repeated measures mixed model ANOVA was used to test for effects of tissue
and lactation, as described in Methods. A statistically significant difference was
determined to exist when the physiologic state effect (comparison between all
control samples against all lactating samples) yielded a p< 0.05 and the effect of
lactation within a given tissue (physiologic state simple effect) yielded a p< 0.01.
Analyzed data are available in Additional File 3.1:
Statistical_Analysis_and_Statistical_Pattern_Matching_Results.txt. These pvalues were used as cutoffs for differentially expressed genes and led to the
proportions of false positives that are listed in the section titled “Approximation of
false discoveries” below.

A number (1,114) of genes demonstrated an interaction at p< 0.01 and 556
genes passed a Benjamini-Hochberg false discovery rate correction at FDR=0.05
(Additional File 3.2: Benjamini_Hochberg_False_Discovery_Rates.txt). These
genes represent those that displayed a different response to lactation in one
tissue with respect to the other tissues. However, it should be noted that this list
was not a useful cutoff, as genes that responded uniformly to lactation across all
tissues would be ignored. Also, five genes that passed the Benjamini-Hochberg
correction did not show any significant changes at p<0.01 when the effect of
lactation was tested within each tissue. Since the primary purpose of this study
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was to characterize the influence of lactation on gene expression on these
tissues, the interaction term was not used. The tissue effect p-values indicated
that many (70% at p<0.01) genes were differentially expressed across tissues,
due to the large difference in cell types between the liver and the small intestine.
Therefore, we chose the cutoffs of a physiologic state main effect at p<0.05 and
the effect of lactation within at least one tissue at p<0.01, as described in the
Methods.

Although not as many genes were detected as significantly differentially
expressed compared to the overall tissue effect, the overall physiologic state
effect and the pairwise comparisons (effect of lactation in each tissue) showed a
high number of low p-values, indicating that the tissues in question responded to
lactation at the level of mRNA. Several genes were downregulated in the
duodenum only (34 genes), with 23 genes showing over a 50% decrease.
Members of this group are listed as pattern “-100” in Additional File 3.1.
Histograms displaying the distribution of p-values are in Additional File 3.3:
Histograms_of_p_values.ppt , and volcano plots displaying each tissue’s
response to lactation are in Additional File 3.4: Volcano_plots.pdf.

Approximation of false discoveries

The proportion of false positives is an approximation of the ratio of false positives
in the list of genes listed as differentially expressed. An estimate of the number
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of false positives was calculated for all tissues using genes where p<0.05 for an
overall physiologic state effect, and for each tissue using genes with an effect of
lactation within each tissue (here defined as a simple effect) of p<0.01. Thus, the
proportion of false positives (PFP) was calculated as (p-value cutoff X number of
genes tested)/number of genes detected below the p-value cutoff. The PFP as
defined by Fernando et al [120], is E(V)/E(R) where E(V) is the expected number
of false rejections of the null hypothesis and E(R) is the expected number of
rejections of the null hypothesis. Here we utilized the actual number of rejections
of the null hypothesis as the expected value. Of all of the genes on the chip,
14,129 genes were found to be annotated and expressed in at least one tissue/
physiologic-state combination and were used for statistical tests. Of those
genes, 1,924 had an overall physiologic state p-value of less than 0.05, yielding a
PFP of 0.37; at an overall physiologic state p<0.01, 690 genes were detected,
yielding a PFP of 0.20. PFPs for the individual tissues at a cutoff of p<0.01 for
the pairwise comparisons (simple effects) were 0.17 for the liver, 0.28 for the
duodenum, 0.22 for the jejunum, and 0.18 for the ileum. The PFPs for the
individual tissue calculations examined only the genes detected at a simple effect
p<0.01, and not at the combined overall physiologic state cutoff of p < 0.05
together with the within-tissue cutoff of p< 0.01, as some genes passed the p<
0.01 cutoff within a given tissue, but did not pass the initial overall physiologic
state effect cutoff of p< 0.05. The rationale for not utilizing the overall physiologic
state effect together with the within tissue physiologic state effect in the
calculation was that these multiple tests were utilized for the same gene.
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Consequently, the list of genes reported at both p<0.05 for the physiologic state
and p<0.01 for the comparison within a tissue was a subset of the list of genes
that only show a p<0.01 within a tissue. The physiologic state cutoff of p< 0.05
was chosen to protect against repeated testing for each tissue; this value was
also chosen because changes that only occurred within one tissue would be
difficult to detect if the overall physiologic state cutoff was made at p< 0.01.
Approximations of the proportion of false positives in this range (0.17 – 0.28)
have been reported previously [121].

RT-PCR Validation of Microarray Data

Results from RT-PCR analyses agreed with the trends detected in the microarray
analyses (Table 3.1). In some cases, significance calls differed, but the
directionality of the changes observed was consistent with the microarray data.
Possible causes for disagreement included the fact that different methods of
normalization were used between RT-PCR and the microarray.

Patterns

Patterns were identified using statistical pattern matching [122, 123] by assigning
each gene as significantly “up”, “down”, or “no change” detected in each tissue.
The results of the statistical pattern matching showed that fifteen genes were
upregulated in all four tissues, while thirty-one genes were downregulated in all
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four tissues. Seventy-two genes were upregulated in liver only, and another
ninety-nine genes were downregulated in liver only. Results from analyses of
each pattern using DAVID [104] are shown in additional file 3.5:
DAVID_output_file.txt.

Of the fifteen genes upregulated in every tissue (Table 3.2), seven were
identified by DAVID as being involved in the Biosynthesis of Sterols pathway,
where p=4.59X10-13, using the list of “Up in All Tissues” for the DAVID analysis.
One gene, transmembrane protein 97 (Tmem97), has been identified as being
regulated by the Srebp proteins [88, 124], and was recently suggested to aid in
Low density lipoprotein receptor (Ldlr) function [124]. Amongst genes not
associated with biosynthesis of sterols, RNA (guanine 9) methyltransferase
domain containing 2 (Rg9mtd2), is the homolog for a tRNA methyl transferase
that occurs in yeast [125]. Slc39a4_predicted was upregulated in all tissues,
consistent with increased zinc absorption during lactation, and is discussed
further below.

Thirty-one genes were identified as downregulated in all tissues (Additional File
3.6: Genes_with_decreased_mrna_all_tissues.pdf). According to the overrepresentation analysis in DAVID, the KEGG T cell receptor pathway was overrepresented in this group (p=0.004) [105, 126] (Additional File 3.5), although only
three genes appeared in this list. This pathway did not pass any of the multiple
testing procedures available in DAVID, but is consistent with the IPA results,
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which flagged “T-cell signaling and differentiation” to be downregulated in the
jejunum and ileum (Figure 3.1).

Genes downregulated only in the duodenum were also investigated using
DAVID, as several genes revealed a strong downregulation in this tissue
(Additional File 3.5). Many of these genes have been identified as being
expressed in the pancreas, i.e., eight of the 34 genes in this group matched the
Sp_PIR keyword “pancreas” (p=5.00X10-15). The function of these genes in the
duodenum and the reason for their poor expression in lactation is not known.

The list of genes upregulated in all parts of the small intestine was not
significantly enriched by any KEGG pathways in DAVID. The term Lipid
Biosynthetic Process was overrepresented (p=0.001), although this term did not
pass any multiple testing correction available in DAVID.

“The Fibronectin Type III fold” Interpro entry was flagged as overrepresented in
the list of genes downregulated in the small intestine, but not in liver. [The genes
associated with the Fibronectin Type II fold entry were Interleukin receptor 22,
alpha 2 (Il22ra2), Immunoglobulin superfamily 9 (Igsf9), Insulin receptor (Insr),
Rims binding protein 2 (Rimbp2), and Protein tyrosine phosphate receptor type g
(Ptprg)]. However, the relevance of the downregulation of these genes in
lactation is not known.
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Categories overexpressed in the list of genes upregulated in the liver only
included the gene ontologies for “response to nutrient levels” and “cholesterol
metabolic process”. The list of genes downregulated in the liver showed the
gene ontology associated with positive regulation of programmed cell death and
may partially explain the increased liver size during lactation [8, 127].

Bile acid biosynthesis
Expression of Cyp7a1, the enzyme catalyzing the rate limiting step of bile acid
biosynthesis, was detected to be increased (p=0.0002) in the liver with a 1.76fold change. Few other changes were detected in the bile acid biosynthetic
pathway. Expression of Cyp46a1, Ch25h, Cyp27a1, Cyp39a1, Cyp7b1, Cyp8b1,
Akr1d1, Slc27a5, Acox2, Scp2, and Baat [128] did not show a significant change
in the liver, suggesting that the increase in bile acid biosynthesis observed was
triggered by the increase in Cyp7a1 mRNA [10]. These data are consistent with
our earlier detailed characterization of mRNA and protein expression of Cyp7a1,
Cyp27a1 and Cyp8b1 in lactation [10].

Ingenuity Pathways Analysis

The lists of differentially expressed genes for each tissue, based on the overall
physiologic state effect p-value and the respective simple effects were examined
by IPA. The three overrepresented pathways with the lowest p-values in each
tissue are shown in Table 3.3, and selected pathways are discussed below.
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Cholesterol synthesis and metabolism

“Biosynthesis of steroids” had the lowest p-value among IPA’s “Canonical
Pathways” in three of the four tissues, with the jejunum being the exception. At
the designated cutoff (p< 0.01), the jejunum showed a much more modest
change in the “biosynthesis of steroids” pathway (p = 0.011 for
overrepresentation in jejunum; p<1X10-6 in all other tissues). Detailed
visualization of the pathway revealed that the upregulated sections of the
“biosynthesis of steroids” pathway corresponded with cholesterol synthesis
(Additional Files 3.7-3.10: Biosynthesis_of_sterols_in_liver.jpg,
Biosynthesis_of_sterols_in_duodenum.jpg,
Biosynthesis_of_sterols_in_jejunum.jpg, and
Biosynthesis_of_sterols_in_ileum.jpg). Since cholesterol synthesis is regulated
by Srebp proteins, Srebp-regulated genes were investigated further. To
determine if an exceptionally large number of Srebp-regulated genes were in the
list of differentially expressed genes, a list of genes shown to be regulated by
Srebp by detection through microarray analysis in Srebp-overexpressing and
Scap knockout mice was used for a right-tailed Fisher’s Exact test [87] using an
online calculator (www.Langsrud.com/Fisher.htm). Here, a p-value of <0.01 in
the tissue being tested was defined as a positive test for the purpose of
determining whether a given gene was differentially expressed.
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Of the 33 genes reported to be regulated by nuclear Srebp proteins [87], 29 were
present in the data set. A Fisher’s exact test p-value of p<0.001 was calculated
for each tissue, with the jejunum (p=0.00029) having the fewest genes displaying
a significant change (eight genes). Additional File 3.11:
Genes_Regulated_by_Srebp_proteins.pdf lists members of the cholesterol
biosynthetic pathway and other genes that have been shown to be differentially
expressed in Srebp-overexpressing mice and Scap knockout mice [87] and
indicates the p-values for each tissue and the ratio of the background-corrected,
normalized, untransformed intensities (lactation intensity/control intensity). As
shown in Figure 3.2, Hmgcr mRNA expression was increased in three of the four
tissues, with no change detected in the jejunum (p = 0.14). mRNA expression for
the genes (Srebf1, Srebf2) encoding the Srebp proteins were not differentially
expressed, although a tendency for a change was detected in the jejunum, where
the simple effect comparison p-value for Srebf1 was 0.0006, and the overall
physiologic state effect p value was 0.054. Expression of Insig1 mRNA, which is
regulated by Srebp activity, showed a significant increase in each part of the
small intestine. In contrast, an increase in Scap mRNA occurred in the liver only
(p = 2.18E-7). Ldlr mRNA was upregulated in the duodenum and jejunum, and
Tmem97 mRNA, an Srebp target [124], was upregulated in all tissues; both Ldlr
and Tmem97 proteins aid in LDL uptake by cells [124].

Cholesterol uptake
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The only gene known to mediate cholesterol uptake in the gut, Npc1l1 [129], is
not contained in the extended dataset for the Affymetrix Rat Exon 1.0ST.
Investigation of the “full” and “all” datasets indicated that no probeset on the chip
was annotated as Npc1l1. Therefore, expression of Npc1l1 was investigated by
RT-PCR (Table 3.1).

No significant changes were detected in Npc1l1

expression in any tissue. Abcg5 and Abcg8, which function as a heterodimer to
efflux cholesterol from the enterocyte into the gut lumen and from the hepatocyte
into bile [130], showed decreased expression in the liver (Abcg5 p=2.9X10-7;
Abcg8 p=3.6X10-6) and in the ileum (Abcg5 p=0.0062; Abcg8 p=0.0048) (Table
3.4).

Transporters

The ATP binding cassette (ABC) transporters that showed a significant change in
at least one tissue were also investigated (Table 3.4). The ABC transporters are
a superfamily of membrane transporters with diverse substrates that in
eukaryotes mediate the ATP-dependent efflux of endogenous substrates,
including bile acids and cholesterol, as well as of xenobiotics, including many
drugs. The ABC transporter Abcb1a (Mdr1a) was downregulated in every tissue.
This protein effluxes xenobiotics across the apical domain of the hepatocyte into
bile, and in the enterocyte and plays an important role in limiting absorption of
orally administered substrates [131]. Two members of the Abcc (Mrp) subfamily,
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Abcc5 and Abcc6, were downregulated in the ileum, while Abcg2 expression was
increased in the duodenum.

Solute carrier proteins (Slcs) are a superfamily of proteins that transport many
different molecules, including amino acids and ions (www.bioparadigms.org). All
Slcs on the chip were investigated and those with a detected significant change
in lactation in any tissue are shown in Additional File 3.12: Slcs.pdf. For each
tissue, nearly 20% of the Slcs showed a change at an overall physiologic state
effect of p <0.05, and approximately 5% were declared significant after applying
a p<0.01 cutoff within a tissue (simple effect)

Slc39a4 is a transporter mediating the uptake of zinc into the intestine [132].
Slc39a4_predicted was one of fifteen genes to be significantly upregulated in
every tissue (p<1X10-5) (Additional File 3.1). Fold changes for Slc39a4 predicted
based on untransformed intensity values ranged from 1.65 in the jejunum to 2.81
in the liver (Table 3.1).

Thyroid signaling

A Fisher’s exact test using IPA detected significant overrepresentation in the
TR/RXR pathway in every tissue. (Additional Files 3.13-3.16:
Liver_canonical_pathways.txt, Duodenum_canonical_pathways.txt.,
Jejunum_canonical_pathways.txt., and Ileum_canonical_pathways.txt). Thyroid
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hormone receptor α (TRA, Thra) and thyroid hormone receptor β (TRB, Thrb)
were both downregulated in the ileum and jejunum. A decrease was also seen in
the liver, but the change was not significant (p = 0.07 for TRA; p = 0.018 for
TRB).

Surprisingly few of the downstream genes of TR/RXR were

downregulated in the IPA depiction of this pathway. In some cases, overlap
occurred with Srebp signaling, and increased signaling from Srebp appeared to
have overridden decreased thyroid signaling. This seems to have occurred with
Acetyl-CoA Carboxylase alpha (Acaca) in the liver and Ldlr in both the duodenum
and jejunum [87]. One TRB/RXR regulated gene [24], Kruppel like factor 9
(Klf9), which is a transcription factor associated with intestinal proliferation, was
downregulated in every tissue (Additional Files 3.17-3.20:
Liver_thyroid_pathway.jpg, Duodenum_thyroid_pathway.jpg,
Jejunum_thyroid_pathway.jpg, and Ileum_thyroid_pathway.jpg). Klf9 knockout
mice have shorter intestinal villi, although Klf9 is typically considered a
transcriptional repressor and can also negatively regulate growth [33].

Decreased mRNA from T-Cell receptor signaling and related pathways

mRNA of genes coding for the components of T-Cell receptor signaling pathway
in IPA showed significant downregulation in the jejunum and ileum (p = 1.68X10-7
and p = 4.7X10-4, respectively) (Figure 3.1). A similar pathway, the “CD28
receptor signaling in T helper cells” pathway was also downregulated in the
jejunum, but substantial overlap between the two pathways suggested
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observation of the same events. These pathways are upstream of IL-2
production [133], however, the microarray detected no change in IL-2 mRNA in
any tissue.
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Discussion

Cholesterol Biosynthesis

IPA and DAVID both flagged “Biosynthesis of Steroids” to be overrepresented in
the list of differentially expressed genes in lactation in three of the four tissues
(the jejunum displayed a p-value near the cutoff), and the list of genes
upregulated in all tissues during lactation, respectively (Additional Files 3.7-3.10).
Visualization of this pathway revealed that the genes identified were components
of the cholesterol biosynthetic pathway. Statistical pattern matching as well as
results from overrepresentation analyses in both DAVID and IPA indicated that
expression of cholesterol biosynthetic genes was induced in all tissues
examined, although to a lesser extent in the jejunum (p=0.011; BenjaminiHochberg corrected p=0.048, values calculated by IPA). Cholesterol and lipid
biosynthetic genes are known to be regulated by transcription factors known as
the Srebp proteins. Three Srebp proteins are encoded by two genes, Srebf1 and
Srebf2. Srebf1 codes for Srebp-1a and Srebp-1c, while Srebf2 codes for Srebp2. The Srebp proteins differ in their control of fatty acid synthesis and cholesterol
biosynthesis [88, 91, 134]. Srebp-2 is associated with cholesterol biosynthesis,
while the Srebp1 proteins are associated with fatty acid synthesis [88], although
there appears to be overlap in the genes that are responsive to these
transcription factors [87]. Srebp-1c is sensitive at the transcriptional level to LXR
signaling [91, 135, 136], while all three share a mechanism for becoming an
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active transcription factor [91]. Under conditions of sufficient cholesterol
concentrations, the protein product of Insulin stimulated gene (Insig) binds to
Srebf Chaperone (Scap) to retain an Insig/Scap/Srebp complex in the
endoplasmic reticulum [91, 137]. In the absence of oxysterols and cholesterol,
Insig is degraded and Scap is released from the endoplasmic reticulum; Scap
then escorts the bound Srebp to the Golgi, where the N-terminus of the Srebp is
cleaved from the full protein to generate the active form that functions as a
transcription factor [134]. As indicated above, cholesterol synthesis is increased
during lactation in both the liver and the small intestine [2, 3] and Srebp target
genes have also been shown to be upregulated in mammary tissue in lactating
dams [89]. In a review article, Shimano lists in a table (Shimano, Table 1) a
series of genes with known SRE elements and their promoter sequences [138].
Of the genes in this table, low density lipoprotein receptor (Ldlr), HMG CoA
synthase1 (Hmgcs1), HMG CoA reductase (Hmgcr), farnesyl diphosphate
farnesyl transferase 1 (Fdft1), Cytochrome P450 family 51 (Cyp51), Acetyl CoA
carboxylase (Acc), Stearoyl CoA desaturase 2 (Scd2), and malic enzyme 1
(ME1) are all upregulated in at least one tissue.

The observation that Srebp-regulated genes were upregulated is consistent with
early data showing an overall increased cholesterol biosynthesis in lactation [9].
We currently do not know which Srebp isoforms are involved in the changes
seen in lactation, as Srebp-1c, Srebp-1a and Srebp-2, are all able to regulate
expression of cholesterol synthetic genes. However, Srebp-2 plays a stronger
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role in regulating these genes [88]. The only potential change detected in the
mRNA for a Srebf gene was Srebf1, the gene associated with Srebp-1a and
Srebp-1c, which showed increased mRNA levels in the jejunum.

In the liver, Scap mRNA showed a significant increase (p = 2.2X10-7). If this
change were associated with an increase in Scap protein levels, then a probable
mechanism for the increase in Srebp target genes in the liver would be increased
transport of Srebp proteins to the Golgi, and their subsequent delivery to the
nucleus [91]. Insig1 mRNA also showed a significant increase in all parts of the
small intestine, but not in the liver. Insig1 functions to retain Srebp in the
endoplasmic reticulum. Thus, increased expression of Scap in liver and
increased expression of Insig1 in intestine provide a likely mechanism for the
greater increase in cholesterol synthesis in liver vs. intestine observed by
Feingold et al [9].

A number of factors contribute to the increased need for cholesterol in the
lactating dam. The dam requires significant cholesterol for the increased
synthesis of bile acids; 50% of cholesterol catabolized in the liver from
nonlactating rats is used for bile acid synthesis [139]. Since the size of the bile
acid pool increases 2-3-fold at 10 -14 d of lactation [10], greater than 50% of
cholesterol is likely catabolized to bile acids in lactation. The proportion of
dietary cholesterol vs. endogenously synthesized cholesterol that is catabolized
to bile acids in nonlactating vs. lactating rats is not known. Most importantly,
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cholesterol is an essential component of milk that supports membrane synthesis
and neurodevelopment in the pups [140]. About 16 mg per day of cholesterol is
secreted into the milk in rats [141]; between 32 and 40% of this cholesterol is
synthesized in the mammary gland, while 11% is absorbed from the diet [86].
Thus, cholesterol synthesized in the liver makes up about 50% of cholesterol
secreted in milk [86].

In addition to detecting a change in cholesterol synthesis, a possible mechanism
for improved net cholesterol uptake was found. Abcg5 and Abcg8 show
decreased levels of mRNA expression in the liver and ileum. A decrease in the
concentration of active Abcg5/Abcg8 heterodimer in the intestine would be
expected to yield an increase in net cholesterol uptake through decreased efflux
from the enterocyte into the gut lumen, while decreased hepatic expression
would minimize cholesterol secretion into bile [93]. The decreased expression of
Abcg5/g8 mRNA in the liver, together with increased expression of cholesterol
synthetic genes, likely serve to enhance conservation of cholesterol to allow for
sufficient transfer of cholesterol into the milk and for synthesis of bile acids.
Increased synthesis of bile acids would in turn serve to increase cholesterol
absorption [90]. Taken together, these data suggest a concerted mechanism for
enhancing net cholesterol absorption and minimizing its elimination to ensure
sufficient cholesterol for incorporation into milk and bile acid synthesis, both
important factors in maintaining the health of both the dam and pups.
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Zinc

Statistical pattern matching found that Slc39a4_predicted mRNA was increased
(1.65 to 2.81 fold) in all tissues. Slc39a4 is a major zinc transporter associated
with zinc import into the enterocyte [132], and zinc absorption is up-regulated in
lactation [73-76]. Taken together, these data imply that the increased expression
of Slc39a4 mediates the increased zinc absorption that occurs in lactation. Zinc
is an essential nutrient shown to be important in bone development [75], to play a
role in stimulating the insulin pathway [142] and in controlling T-Cell activity [143].
Zinc requirements are increased during lactation relative to pregnancy, and
therefore net zinc uptake needs to be increased to maintain zinc homeostasis
during lactation in humans, particularly during early lactation [144]. Interestingly,
alpha-2-macroglobulin (A2m) showed a substantial increase in mRNA expression
(~15-fold) in the liver. Zinc can directly regulate A2m’s ability to sequester
cytokines [143, 145, 146] by enhancing formation of a form of A2m that contains
free sulfhydryl groups, which serve as binding sites for the cytokines [146].

Downregulation of mRNA from the T-Cell signaling pathway

Both the jejunum and ileum showed strong downregulation at the mRNA level of
the proteins composing the T-Cell signaling pathway in IPA. These changes may
reflect a decrease in the number of actual T-Cells in the small intestine of
lactating rats.
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Xenobiotic Transporters

Table 3.4 displays significantly different changes in mRNA concentration for the
ABC transporters. Included in this list of genes are Abcb1a (Mdr1a), Abcc5,
Abcc6, and Abcg2. Abcb1a showed decreased expression in all tissues in the
microarray and this was successfully validated for the jejunum and ileum by RTPCR. Abcc5 and Abcc6 also showed decreased mRNA expression in the ileum.
Decreased expression of these efflux transporters would in general lead to an
increased net absorption of their substrates. In contrast, Abcg2 showed
increased expression in the duodenum, which would decrease absorption of
substrates. Sample substrates for these proteins include drugs such as digoxin
and cyclosporine A (Abcb1a, [147]), cGMP (Abcc5 [148]), the glutathione
conjugate leukotriene C 4 (Abcc6 [149] [150]), and 2-amino-1-methyl-6phenylimidazo[4,5-b] pyridine, a dietary carcinogen (Abcg2 [151]). Further work
is needed to understand the impact of these specific changes within the context
of lactation on the lactating dam and her pups.

TR/RXR Pathway

IPA found members of the TR/RXR pathway to be overrepresented in the list of
differentially expressed genes in each tissue. In both the ileum and jejunum, both
TRA and TRB showed down-regulation. Although lactating rats are hypothyroid
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[19] and expressed lower levels of mRNA for thyroid receptor in these tissues,
not all thyroid responsive genes were down-regulated, including Apoa5, Eno1,
and Glut1, which showed no change in any tissue. A more detailed picture of the
thyroid receptor pathway can be found in Additional Files 3.17-3.20. Serum
thyroid hormone levels and early steps in the pathway are likely downregulated
as an attempt to conserve energy [19, 152]. Fisher’s exact test determines its pvalues based on the counts of the number of genes in the list of differentially
expressed genes and compares these to the total number of genes in the
pathway relative to the total number of genes in the microarray. Therefore,
pathways that overlap are likely to be detected as overrepresented if the
overlapping genes are in the list of differentially expressed genes. Because
some Srebp regulated genes are considered to be part of the TR/RXR pathway,
the p-values for overrepresentation may be low, even if thyroid signaling overall
was unchanged. However, changes in the mRNA levels of the thyroid receptors
argue against this, since these receptors have not been shown to be Srebp
targets.
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Conclusions

The present studies have shown an increase in the mRNA of enzymes involved
in the cholesterol biosynthesis pathway, implying that the sterol regulatory
element binding proteins are more active in the liver and small intestine in
lactating vs nonlactating rats. The data are consistent with a coordinated
response to the overall increased energy demands of lactation and the specific
needs of the pups for cholesterol so that there is adequate cholesterol for
incorporation into milk and increased synthesis of bile acids; the latter in turn
function to increase the intestinal absorption of cholesterol and lipids. We also
demonstrated a marked increase in the expression of a key transporter important
in the uptake of the essential element, zinc. Finally, we detected decreased
mRNA from genes associated with T-cell signaling in the jejunum and ileum.
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Methods

Animals

Sixteen Sprague-Dawley rats that were lactating for 10-11 days and sixteen agematched virgin controls were obtained from Harlan (Indianapolis, IN) and
maintained on a 12 h light/dark cycle (6 AM lights on/6 PM lights off). Rats had
free access to Teklad Global Diet 2018 (Harlan Laboratories, Cincinnati, OH) and
water. In order to minimize the variance in energy demands on the lactating dam,
pups were removed from large litters within 24 hours of birth so that all litters
contained 8-11 pups. All animals were sacrificed at 16 h (10 h of light on a 12 h
light/dark cycle; 4 PM), and the liver, duodenum, jejunum, and ileum were
removed for total RNA extraction from each tissue. The first 5 cm of the small
intestine following the pyloric sphincter was taken as the duodenum, while the 10
cm following the ligament of Trietz was discarded and the next 20 cm used as
the jejunum. The 20 cm segment preceding the cecal valve was taken as ileum.
The mucosal layer was removed by scraping at 4°C, and used for isolation of
RNA from intestinal segments. RNA was extracted from homogenized tissue
using Trizol (Invitrogen, Carlsbad, CA), and purified using RNeasy Mini Kit
DNAse and columns (Qiagen, Valencia, CA). The integrity of all RNA samples
was verified using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA). Animal protocols were conducted in accordance with the National
Institutes of Health Guidelines for the Care and Use of Laboratory Animals and
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were approved by the Institutional Animal Care and Use Committee of the
University of Kentucky.

Each rat was assigned to one of four pools within the respective physiologic state
(four control pools and four lactating pools). Pooled RNA samples, consisting of
the RNA from the four rats within the same group, were created for each tissue,
with individual rats composing the pools consistent across tissues. Each pooled
sample (RNA from one tissue from one set of four rats) was loaded onto a
separate chip. This resulted in the use of 32 chips (4 tissues X 2 “physiologic
states” X 4 pools). Samples were prepared and processed according to the
manufacturer’s instructions by the University of Kentucky Microarray Core Facility
(Lexington, KY).

Selection of Genes on Which to Perform Statistical Analysis

Affymetrix Expression Console software was used to perform the Robust
Multichip Average (RMA) [99, 100] algorithm, which background corrected,
quantile normalized, and log 2 -transformed gene level summaries of the Extended
dataset. Affymetrix has divided the chip into various datasets, which represent
different confidence levels with respect to the complementarities between the
probe and the sense strand of the gene sequences. The Extended dataset
consists of the Core dataset, which is made up of Refseq entries and full length
mRNAs, as well as additional multiple annotations based on cDNA libraries.
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Although the Core dataset probes are the best annotated, the rat genome is not
as well annotated as the human and mouse genomes, with many of the genes in
the rat Extended dataset identified based on their similarity to human or mouse
genes. Use of the Extended dataset allowed a more thorough analysis of the
genome. The summarized values are an average taken across all exons.

The exon level Affymetrix DABG (Detection Above Background) values and the
Affymetrix annotation file (version raex_1_0-st-v1.na27.rn4) were used to filter
the data [110]. Exon level data was opened in Expression Console and the RMA
algorithm and log 2 transformations were performed. An exon was considered
present if it had a DABG p < 0.01, indicating that the exon in question had an
intensity greater than 99% of the background probes with the same GC content
[110]. A gene was considered for analysis if at least one exon was detected on
at least two chips within the same tissue and the same physiologic state, e.g.,
presence on two control liver chips. Genes were also removed if the Affymetrix
annotation file contained a “---“ or a blank for the “mRNA description” entry
(Annotation file: raex_1_0-st-v1.na27.rn4). Of the 19,434 genes in the Extended
dataset, 14,129 were utilized for statistical tests based on these criteria.

Statistical Analysis

Since all four tissues were taken from each rat, a repeated measures mixed
model ANOVA was used to determine if changes in expression were statistically
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significant for each gene [153]. JMP genomics version 4.1 (SAS Institute Inc,
Cary, NC, 2011) was used to perform the ANOVA using compound symmetry to
model the covariance matrices. Tissue, physiologic state, and the
tissue*physiologic state interaction were treated as fixed effects, while “pool”, a
variable describing the combination of four individual rats to create a sample,
was treated as a random subject variable.

A common method for addressing multiple testing issues involved in the analysis
of microarrays is the Benjamini-Hochberg false discovery rate (FDR) correction.
Several possibilities existed for attempting to address the issue of multiple
testing. First, the physiologic state p-value could be adjusted to a fixed FDR.
Alternatively, the individual unadjusted p-values for the simple effects could be
set to a given value and an approximation of the number of false positives within
a group could then be calculated. We chose the latter approach, set p<0.01 as a
cutoff and calculated the proportion of false positives (PFPs) for the simple
effects that represented the pairwise comparisons within a tissue. We chose this
method to balance the risk of false positives with the risk of false negatives.
False negatives in the list of differentially expressed genes could interfere with
downstream pathway analyses.

The overall physiologic state effect of p< 0.05 also served as an additional cutoff
to reduce the total number of statistical tests performed. Selection of an overall
physiologic state p-value of p< 0.01 was problematic, as genes that displayed
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differential expression in only one tissue might not be noticed due to the lack of
change in the remaining tissues. In summary, genes were considered
differentially expressed between control and lactation within a tissue if a
significant physiologic state effect was observed at p<0.05 and a simple effect for
the pairwise comparison within a tissue was p< 0.01.

.CEL files and .CHP files describing the data are available through GEO under
GSE19175 and analyzed data is available in Additional File 3.1.

Detection of Biological Trends

Ingenuity Pathways (IPA) (www.ingenuity.com) was used to screen the results
for biological trends. Differentially expressed genes were determined as
described in the “Statistical Analysis” section above. The Rat Exon 1.0 ST chip
was used as a background list.

A right tailed Fisher’s Exact test was used to screen the IPA database and detect
categories that were overrepresented based on genes detected to have a
significant difference in expression. Available in IPA is the Benjamini-Hochberg
correction, which attempts to control the number of false positives. This
calculation is dependent on the size of the database. We chose not to use the
Benjamini-Hochberg correction, but chose to fix the significance threshold at
p<0.01 for any given test. A p< 0.01 for the Fisher’s Exact test indicated that
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more genes in the list of differentially expressed genes appeared in a pathway
than would be expected by chance if the same number of differentially expressed
genes were to be selected randomly from all genes on the chip. Both these pvalues and the Benjamini-Hochberg p-values are provided in Table 3.3.

The lists generated by statistical pattern matching were analyzed by DAVID [104,
105] with the 14,129 genes used for statistical analyses as the background list.
The lists screened for overrepresentation were the Canonical Pathways category
in IPA and several databases in DAVID (see below). For the Srebp transcription
factors, a report of the differential gene expression in mice overexpressing
isoforms of Srebp and in Scap knockout mice was used to create an additional
list of genes known to be regulated by the Srebp proteins [87]. Out of the 33
genes listed as regulated by nuclear Srebp-1a and Srebp2, 29 were identified as
being on the chip at the level of the Extended dataset and were used to perform
a right tailed Fisher’s Exact test.

We used IPA’s Canonical Pathways database for all changes detected within a
tissue, while we used all Gene Ontology terms, COG ontology, Sp_PIR Keyword
[154, 155], UP_SEQ_Feature [154, 155], Interpro [156], PIR_Superfamily [157],
SMART [158, 159], and KEGG [126, 160, 161] as databases in DAVID for testing
each pattern detected by statistical pattern matching.

Statistical Pattern Matching
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In order to assign changes of RNA expression into biologically meaningful
groups, a method of statistical pattern matching was used analogous to the one
used by Arzuaga et al [122] and Hulshizer and Blalock [123]. mRNA from any
given gene could increase expression, decrease expression, or show no change
in expression in samples from lactating animals compared to controls in each
tissue. The method for pattern matching is described in a step by step manner
as follows. Only genes that tested positive for differential expression were used
for pattern matching. These genes were assigned an additional significance call
at p<0.05 for each simple effect within a tissue. This was done to protect against
incorrectly assigning a gene that systematically had low p-values as differentially
expressed in only one tissue. For example, if a gene was downregulated with p
values of less than 0.01 in the liver, duodenum, and jejunum, and a p of 0.03 in
the ileum, the gene was assigned as differentially expressed in all tissues rather
than in three of the four tissues. Although the gene would not have been
considered differentially expressed for the purposes of evaluating which genes
were differentially expressed in the ileum, the gene was considered differentially
expressed for the purposes of assigning a pattern. This reduced the risk of
falsely assigning the gene to another pattern in the presence of a false negative.
The fold-change within a given tissue was then utilized to determine if a gene
was upregulated or downregulated in each tissue. For each tissue, three values
were multiplied to define the change in that tissue. One value was an integer
that represented the tissue itself: 1000 for liver, 100 for duodenum, 10 for
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jejunum, and 1 for ileum. The second value was a multiplier to define whether or
not there was a tendency (p<0.05) for the gene to change expression in the given
tissue, where p<0.05 = 1; p>0.05 = 0). The third value defined the directionality
of the change, where upregulation = 1 and downregulation = - 1. The products of
these values were used to define the change that occurred within a given tissue.
For example, a gene upregulated in the liver would have a value of 1000, i.e.,
1000*1*1. The sum of this value for all tissues was taken to generate a unique
value for every set of possible changes that could occur across tissues. For
example a gene that was upregulated in every tissue except the ileum, where it
was downregulated would have a value of 1009 (1000 + 100 + 10 - 1).

The

following groups were defined to be of particular importance and were
investigated: up in all tissues, down in all tissues, up in all parts of small intestine,
down in all parts of small intestine, up in liver, down in liver, and down in
duodenum only.

RT-PCR validation of microarray findings

The same total RNA samples used for the microarray were used for RT-PCR
validation; RT-PCR was performed as reported previously [162], using the
geometric average of Ctsb, Tmbim6, and Tmed2 as a normalization constant
[10]. An aliquot of all cDNA samples was used to generate a standard curve.
RT-PCR experiments were performed by Dr. Tianyong Zhao in our laboratory.
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Choosing an appropriate normalization constant was performed using
methodology similar to that described by Andersen et al [163]. Methods for
detecting valid internal controls require a list of candidate genes with little or no
bias, since any bias that exists within the genes detected as valid internal
controls would be transferred over to the newly calculated normalization factor
[163]. Genes with high expression (mean log 2 intensity from the microarray
greater than or equal to 10) were sorted by their coefficients of variance.
Microarray data for the twenty genes with the lowest coefficients of variance were
input into Normfinder [163]. The single best gene to use as a control was Ctsb,
and the best combination of two was found to be Tmbim6 and Tmed2. We
performed RT-PCR on these genes and chose to use the geometric mean of the
three genes as a normalization constant. The same statistical model that was
used to analyze the microarray results was used to analyze the normalized RTPCR data.

cDNA was synthesized using High-Capacity cDNA Reverse Transcription Kits
from Applied Biosystems (Foster city, CA) according to the manufacturer’s
instructions. Primers and Universal Probes Library (UPL) probes for real time RT
PCR were designed and ordered from Roche Applied Science (Mannheim,
Germany) using online software (www.universalprobelibrary.com). A list of
primers is provided in Additional File 3.21: RT_PCR_primers.pdf. The Roche
Light Cycler 480 was used for performing the RT-PCR. Briefly, 1 μg of total RNA
was used for cDNA synthesis, the synthesized cDNA diluted to 500 μL, and 5 μL
67

of diluted cDNA used as template in a 20 μL reaction volume.

For quantification

analysis of real time RT-PCR data, a standard curve was generated by pooling
all the cDNA samples to form one cDNA mixture and then diluting this cDNA
mixture 10-, 100-, 1000- and 10,000-fold so that expression of the gene of
interest was within the range of the standard curve.
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Figures

Jejunum

69

Ileum
70

Figure 3.1. T-cell signaling in lactating jejunum and ileum
Downregulation of T-cell signaling in the jejunum (top, p = 1.68X10-7) and ileum
(bottom, p = 4.7X10-4). Green shading indicates downregulation of the
corresponding gene during lactation.
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Figure 3.2. Plot of Mean Intensities for Known Cholesterol Biosynthetic
Enzymes
The mean untransformed intensities were plotted against tissue/physiologic state
combination. C and L indicate the mean of Control and Lactating samples,
respectively, within each tissue. Abbreviations for genes are as follows. Dhcr7:
7-dehydrocholesterol reductase; Fdft1: farnesyl-diphosphate farnesyltransferase
1; Sc4mol: sterol-C4-methyl oxidase-like; Idi1: isopentenyl-diphosphate delta
isomerase 1; Mvd: mevalonate (diphospho) decarboxylase; Hmgcs: 3-hydroxy-3methylglutaryl-Coenzyme A synthase 1; Hmgcr: HMG Coenzyme A reductase;
72

Lss: lanosterol synthase; Cyp51: cytochrome P450 family 51; Sqle: Squalene
Epoxidase. A red line between Control and Lactating symbols for a given gene
indicates that p>.0.01 for the tissue pairwise comparison within the tissue from
the mixed models repeated measures ANOVA on the log 2 transformed
intensities; the change was not considered significant for the purposes of
determining a list of differentially expressed genes. A black line between C and L
symbols indicates p< 0.01 as described above.
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Table 3.1. RT-PCR validation of selected genes from the microarray.
Transcript
Gene Symbol

Cluster ID

RL

RD

RJ

RIL

7080099

1.52

2.60

1.59

1.73

(p=0.021)

(p<0.01)

(p=0.42)

(p=0.072)

1.92

2.03

1.82

2.15

(p<0.01)

(p<0.01)

(p<0.01)

(p<0.01)

1.00

1.27

1.22

0.88

(p=1.00)

(p=0.49)

(p=0.16)

(p=0.72)

0.82

0.83

0.72

0.65

(p=0.91)

(p=0.77)

(p=0.09)

(p<0.01)

0.63

0.66

0.65

0.70

(p<0.01)

(p<0.01)

(p<0.01)

(p=0.01)

2.98

1.12

2.06

0.78

(p=0.93)

(p=0.64)

(p<0.01)

(p=0.89)

2.29

1.23

1.71

0.67

(p<0.01)

(p=0.35)

(p=0.02)

(p=0.03)

1.83

1.30

(p=0.12)

(p=1.00)

BDL

BDL

1.69

1.23

1.05

1.04

(p<0.01)

(p=0.35)

(p=0.50)

(p=0.58)

1.36

2.58

1.02

2.41

(p=0.11)

(p=0.22)

(p=0.99)

(p=0.018)

1.38

1.98

1.42

1.55

(p<0.01)

(p<0.01)

(p<0.01)

Tmem97
Npc1l1
7250393

Abcb1a
7336681

Cyp1a1
7100149

Cyp3a23/3a1
7139070

Fdft1
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(p<0.01)

7202670

Hmgcr
7329323

Slc39a4

2.05

1.52

1.14

1.18

(p<0.01)

(p=0.30)

(p=0.80)

(p=0.48)

1.97

1.64

1.17

1.38

(p<0.01)

(p<0.01)

(p=0.14)

(p<0.01)

2.71

2.92

2.20

1.99

(p=0.59)

(p<0.01)

(p<0.01)

(p<0.01)

2.81

1.89

1.65

1.68

(p<0.01)

(p<0.01)

(p<0.01)

(p<0.01)

7317317

2.66
1.80

(p=0.03

1.71

1.59

(p<0.01)

4)

(p=0.50)

(p=0.056)

1.83

2.27

1.72

1.70

(p<0.01)

(p<0.01)

(p<0.01)

(p<0.01)

0.85

0.76

0.39

0.62

(p=0.047)

(=0.41)

(p=0.21)

(p=1.00)

Ugt2b36

0.96

0.57

0.37

1.00

(Ugt2b4)

(p=0.86)

(p<0.01)

(p<0.01)

(p=0.97)

Sqle
7117373

Ratios were calculated as Lactating measurement divided by Control
measurement. RT-PCR data is reported as the ratio of normalized
measurements, and microarray data is reported as the ratio of normalized,
untransformed intensities. p-Values were calculated using a mixed models
approach as described in methods. RL, RD, RJ and RIL are the Ratio of
Lactation to Control in liver (L), duodenum (D), jejunum (J), and ileum (IL),
respectively. BDL, below detection limit. RT-PCR results are listed as the top
set of values, and microarray results are listed below.
75

Table 3.2. Genes that displayed increased mRNA during lactation in all
tissues
Transcript
Cluster ID

7027017

7080099

7113785

7132836

7139070

7144691

7166170

7169182

7186293

RL

RD

RJ

RIL

Gene Name
Acetyl-Coenzyme A

1.98

2.40

1.80

2.19

acetyltransferase

(p=0.0173)

(p=0.0049)

(p=0.0363)

(p=0.0128)

1.92

2.03

1.82

2.15

Transmembrane protein 96

(p=0.0001)

(p=2.8e-05)

(p=0.0002)

(p=8.7e-06)

Hydroxysteroid(17-beta)

1.71

1.54

1.19

1.51

dehydrogenase 7

(p=2.1e-06)

(p=4.7e-05)

(p=0.045)

(p=0.0001)

PDZ binding kinase

1.56

1.88

1.66

1.54

predicted*

(p=0.0222)

(p=0.0031)

(p=0.0054)

(p=0.0227)

Farnesyl diphosphate

1.38

1.98

1.42

1.55

farnesyl transferase

(p=0.0009)

(p=4.7e-08)

(p=0.0004)

(p=4.1e-05)

Sterol-C4-methyl oxidase-

1.41

2.19

1.45

1.80

like

(p=0.0015)

(p=1.9e-07)

(p=0.0008)

(p=8.2e-06)

Isopentenyl-diphosphate

1.61

2.11

1.33

1.91

delta isomerase

(p=0.0006)

(p=2.8e-06)

(p=0.0226)

(p=2.6e-05)

Kinesin family member

1.46

1.50

1.33

1.45

20a_predicted*

(p=0.0012)

(p=0.0010)

(p=0.0104)

(p=0.0013)

Mevalonate (diphospho)

2.65

2.15

1.49

1.73

decarboxylate

(p=3.8e-05)

(p=0.0004)

(p=0.0316)

(p=0.0042)

RNA (guanine-9-)

1.18

1.42

1.19

1.30

methyltransferase domain

(p=0.009)

(p=3.6e-06)

(p=0.0066)

(p=0.002)

1.24

2.14

1.50

1.89

7199743

containing 2

7250653

CYP51

76

7280610

7291805

7317317

7329323

(p=0.0116)

(p=1.8e-09)

(p=4.2e-05)

(p=6.7e-08)

UDP-Galactose-4-

1.65

1.50

1.36

1.53

epimerase

(p=0.0006)

(p=0.0042)

(p=0.0243)

(p=0.0023)

Dehydrodolichyl

1.37

1.36

1.27

1.17

diphosphate synthase

(p=0.0003)

(p=0.0005)

(p=0.0041)

(p=0.0447)

1.83

2.27

1.72

1.70

Squalene epoxidase

(p=2.4e-05)

(p=5.6e-07)

(p=0.0001)

(p=0002)

Solute carrier 39 (zinc

2.81

1.89

1.65

1.68

transporter) member 4

(p=2.5e-10)

(p=9.9e-08)

(p=2.1e-06)

(p=1.2e-06)

To be considered part of a grouping, genes must have had a physiologic state p
<0.05 and at least one tissue simple effect p <0.01. Reported p-values are the
tissue simple effect p-values. The tissue simple effect p-value represents the
comparison between Lactation and Control in the corresponding tissue. For the
purposes of assigning patterns, the significance cutoff for the remaining tissues’
simple effect p-values was set to p< 0.05. Abbreviations used as in Table 3.1.
*Gene is at the Extended confidence level.
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Table 3.3. Top three pathways for overrepresentation in each tissue
Liver
Pathway

Fisher’s Exact test

BH

p-value

p-value

Biosynthesis of steroids 3.50E-07

5.80E-05

Members

↑Dhcr7, ↑Fdft1,↑Hmgcr,↑Idi1, ↑Lss, ↑Mvd,
↑Sqle

LXR/RXR Activation

1.57E-04

1.30E-02

↓Abcg5, ↓Abcg8, ↑Acaca, ↑Cyp7a1, ↓Hadh,
↑Hmgcr, ↓Lcat

3.01E-04

1.67E-02

↑Aldoc, ↑G6pd, ↑Gpi, ↓H6pd, ↓Pgm5

Biosynthesis of steroids 1.13E-10

1.74E-08

↑Dhcr7, ↑Fdft1, ↑Fntb, ↑Hmgcr, ↑Idi1, ↑Lss,

Pentose/Phosphate
Pathway

Duodenum
Pathway

↑Mvd, ↑Sc5dl, ↑Sqle
Androgen and

1.35E-04

1.04E-02

↓Srd5a2, ↓Ugt2b7

estrogen metabolism
Glycerolipid metabolism 1.46E-03

↑Ftsj1, ↑Hsd11b1, ↑Hsd17b7, ↑Nsdhl,

7.50E-02

↓Cel, ↓Clps, ↓Glb1l2, ↓Pnlip, ↓Pnliprp1,
↓Pnliprp2

Jejunum
Pathway
T-Cell receptor signaling 1.68E-07

2.78E-05

↓Bmx, ↓Cd8b, ↓Grap2, ↓Itk, ↓Malt1,
↓Pik3cg, ↓Pik3r1, ↓Ppp3cc, ↓Prkcq, ↓Ptprc,
↓Rasgrp1, ↓Trb
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CD28 signaling in

1.17E-05

6.74E-04

↓Pik3r1, ↓Ppp3cc, ↓Prkcq, ↓Ptprc, ↓Trb

T helper cells
TR/RXR activation

↓Grap2, ↓Itk, ↓Malt1, ↑Mapk9, ↓Pik3cg,

1.23E-05

6.74E-04

↑Fga, ↑Gh1, ↓Klf9, ↑Ldlr, ↓Pik3cg, ↓Pik3r1,
↓Thra, ↓Thrb, ↓Thrsp

Ileum
Pathway
Biosynthesis of steroids 9.42E-08

1.71E-05

↑Cyp24a1, ↑Dhcr7, ↑Fdft1, ↑Hmgcr, ↑Idi1,
↑Mvd, ↑Sc5dl, ↑Sqle

TR/RXR activation

3.16E-07

2.86E-05

↑Fga, ↑Gh1, ↓Klf9, ↑Me1, ↓Nfcor2, ↓Pck1,
↓Pik3c2b, ↓Pik3cg, ↓Pik3r5, ↓Ppargc1a,
↓Thra, ↓Thrb

Thrombopoietin signaling 4.85E-05

2.53E-03

↓Irs2, ↓Pik3c2b, ↓Pik3cg, ↓Pik3r5, ↓Plcg1,
↓Plcg2, ↓Prkce, ↓Prkcq

The pathways with the three lowest p-values from Fisher’s exact test for
pathways from IPA’s “Canonical Pathways” database for each tissue are
reported here along with the corresponding p-value from a right-tailed Fisher’s
exact test, the Benjamini-Hochberg (BH) adjusted p-value, and the genes within
the pathway that showed differential expression within the respective tissue
(Members). Arrows in the Members column indicate the direction of change in
lactating animals relative to controls.
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Table 3.4. ATP-Binding Cassette (ABC) transporters detected to be
differentially expressed between Control and Lactating dams.
Transcript
Gene Symbol

Cluster ID

RL

RD

RJ

RIL

7065486

0.888

0.931

0.99

0.8

(p=0.138)

(p=0.329)

(p=0.874)

(p=0.007)

0.567

0.885

0.942

0.763

(p=7.0E-04)

(p=0.273)

(p=0.744)

(p=0.054)

0.63

0.663

0.652

0.697

(p=0.001)

(p=0.002)

(p=0.002)

(p=0.005)

0.818

1.065

0.938

0.672

(p=0.021)

(p=0.476)

(p=0.471)

(p=8E-05)

0.886

0.852

0.884

0.73

(p=0.109)

(p=0.03)

(p=0.089)

(p=2.0E-04)

0.949

1.55

1.049

1.203

(p=0.666)

(p=6.0E-05)

(p=0.613)

(p=0.049)

0.321

0.762

0.901

0.656

(p=3.0E-07)

(p=0.095)

(p=0.515)

(p=0.006)

0.297

0.67

0.803

0.592

(p=4.0E-06)

(p=0.039)

(p=0.261)

(p=0.005)

Abca3
7083965
Abca8a_predicted*
7250393
Abcb1a
7089622
Abcc5
7051110
Abcc6
7254219
Abcg2
7303106
Abcg5
7294657
Abcg8

The p<0.01 column indicates in which tissues a change was detected.
Abbreviations are as defined for Table 3.1. *Gene is at the Extended level of
confidence.
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p<0.01

IL

L

L,D,J,IL

IL

IL

D

L, IL

L, IL

Additional files
Additional File 3.1: Statistical analysis and statistical pattern matching
results (Statistical_Analysis_and_Statistical_Pattern_Matching_Results.txt)
Results from statistical pattern matching are reported as a .txt file. Results are
reported for all 14,129 genes considered for statistical analysis, but genes that
were not differentially expressed in any tissue are assigned a pattern of zero.
Transcript_ID is an identifier associated with the gene analyzed. The gene
assignment entry was taken from the Affymetrix annotation file and displays
which gene is associated with the given transcript ID. Tissue p, physiological
state p, and tissue*physiological state p correspond to the p-values associated
with the tissue main effect, physiological state main effect, and the interaction,
respectively. p Liver, p duodenum, p jejunum, and p ileum represent the pvalues associated with the corresponding simple effects Pattern indicates in
which pattern a gene is detected. A zero indicates no differential expression.
Otherwise, patterns are assigned as described in the Methods. Ratio liver, ratio
duodenum, ratio jejunum, and ratio ileum represent the ratio of the mean of
samples from lactating animals to the mean of samples from controls utilizing the
untransformed microarray data.

Additional File 3.2: Benjamini-Hochberg false discovery rates
(Benjamini_Hochberg_False_Discovery_Rates.txt)
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False Discovery Rate corrections [102] for all genes studied is presented in .txt
format. Transcript_ID is an Affymetrix Identifier for each gene. False discovery
rates are provided for the tissue*physiological state interaction term and the
overall physiological state effect. Q-values were calculated as the number of
false positives expected by chance (uncorrected p* total number of tests) divided
by the total number of results with an equal or lower p-value.

Additional File 3.3: Histograms of p-values (Histograms_of_p_values.jpg)
Histograms for A) tissue effect p-values, B) physiological state effect p-values, C)
physiological state*tissue interaction p-values, and pairwise comparison p-values
for D) the liver, E) duodenum, F) jejunum, and G) ileum presented as a .ppt file.
While a large tissue effect was observed, a visible treatment effect (control vs.
lactation) was also observed.

Additional File 3.4: Volcano plots (Volcano_plots.pdf)
Volcano plots comparing the log 2 fold changes (reported as mean untransformed
lactating intensity divided by untransformed mean control intensity) against the
calculated pairwise comparison p-value for each individual tissue in .pdf format.
Volcano plots are for A) Liver, B) Duodenum, C) Jejunum, and D) Ileum. Each
tissue responded differently to lactation. The blue line indicates the significance
cutoff of p< 0.01. The number of differentially expressed genes were 420 in the
liver, 337 in the duodenum, 402 in the jejunum, and 523 in the ileum, when an
overall treatment main effect p-value cutoff of p<0.05 was incorporated. Of
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particular note is a series of genes that were strongly downregulated in the
duodenum (Additional File 3.1 pattern -100; discussed in Results.)

Additional File 3.5: DAVID output (DAVID_output_file.txt)
DAVID was utilized to test specific patterns from statistical pattern matching.
Patterns were chosen based on similarity between tissues and were “Up in All
Tissues”, “Down in all tissues”, “Up in all parts of small intestine”, “Down in all
parts of small intestine”, “Up only in liver”, “Down only in liver”, and “Down only in
duodenum”. Table truncated from output in DAVID. Genes listed by Affymetrix
transcript cluster ID, which may be referenced in Additional File 3.1.

Additional File 3.6. Genes with decreased mRNA in all tissues
(Genes_with_decreased_mrna_all_tissues.pdf)
To be considered part of a grouping, genes must have a physiologic state p<
0.05 and at least one tissue simple effect p <0.01. Reported p-values are tissue
simple effect p-values and represent the comparison between Lactation and
Control in the corresponding tissue. For the purposes of assigning patterns, the
significance cutoff for the remaining tissue simple effect was set to p <0.05.
Abbreviations used as in Table 3.1. *Gene is at the Extended confidence level.

Additional File 3.7: Biosynthesis of sterols in liver
(Biosynthesis_of_sterols_in_liver.jpg)
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Image from IPA representing the “Biosynthesis of Sterols” in the liver as a .jpg
file. Numbering system for enzymes in the pathway is taken from KEGG [160].
Components of the cholesterol biosynthetic pathway include 1.1.1.34 (Hmgcr),
2.7.1.36 (Mvk), 2.7.4.2 (Pmvk), 4.1.1.83 (Mvd), 5.3.3.2 (Idi1), 2.5.1.21 (Fdft1),
and 1.14.99.7 (Sqle), 5.4.99.7 (Lss), and 1.3.1.21 (Dhcr7). Red shading
indicates increased mRNA during lactation from the corresponding gene.

Additional File 3.8: Biosynthesis of sterols in duodenum
(Biosynthesis_of_sterols_in_duodenum.jpg)
Image from IPA representing the “Biosynthesis of Sterols” in the duodenum as a
.jpg file. Numbering system for enzymes in the pathway is taken from KEGG
[160]. Components of the cholesterol biosynthetic pathway include 1.1.1.34
(Hmgcr), 2.7.1.36 (Mvk), 2.7.4.2 (Pmvk), 4.1.1.83 (Mvd), 5.3.3.2 (Idi1), 2.5.1.21
(Fdft1), and 1.14.99.7 (Sqle), 5.4.99.7 (Lss), and 1.3.1.21 (Dhcr7). Red shading
indicates increased mRNA during lactation from the corresponding gene.

Additional File 3.9: Biosynthesis of sterols in jejunum
(Biosynthesis_of_sterols_in_jejunum.jpg)
Image from IPA representing the “Biosynthesis of Sterols” in the jejunum as a
.jpg file. Numbering system for enzymes in the pathway is taken from KEGG
[160]. Components of the cholesterol biosynthetic pathway include 1.1.1.34
(Hmgcr), 2.7.1.36 (Mvk), 2.7.4.2 (Pmvk), 4.1.1.83 (Mvd), 5.3.3.2 (Idi1), 2.5.1.21
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(Fdft1), and 1.14.99.7 (Sqle), 5.4.99.7 (Lss), and 1.3.1.21 (Dhcr7). Red shading
indicates increased mRNA during lactation from the corresponding gene.

Additional File 3.10: Biosynthesis of sterols in ileum
(Biosynthesis_of_sterols_in_ileum.jpg)
Image from IPA representing the “Biosynthesis of Sterols” in the ileum as a .jpg
file. Numbering system for enzymes in the pathway is taken from KEGG [160].
Components of the cholesterol biosynthetic pathway include 1.1.1.34 (Hmgcr),
2.7.1.36 (Mvk), 2.7.4.2 (Pmvk), 4.1.1.83 (Mvd), 5.3.3.2 (Idi1), 2.5.1.21 (Fdft1),
and 1.14.99.7 (Sqle), 5.4.99.7 (Lss), and 1.3.1.21 (Dhcr7). Red shading
indicates increased mRNA during lactation from the corresponding gene.

Additonal File 3.11. Genes regulated by Srebp proteins
(Genes_Regulated_by_Srebp_proteins.pdf)
Genes that increase expression in Srebp-1a overexpressing mice and Srebp-2
overexpressing mice, and decrease expression in Scap knockout mice [87].
Overrepresentation analysis showed that genes in this list occurred more
frequently than expected by chance in the lists of differentially expressed genes
(p<1X10-4 in each tissue.) Abbreviations used as in Table 3.1. *Gene is at the
Extended confidence level.

Additional File 3.12. Members of the Slc superfamily (Slcs.pdf)
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Table displaying members of the Slc superfamily. The p<0.01 column indicates
in which tissues a change was detected. Abbreviations are as defined for Table
3.1. * Gene is at the Extended level of confidence. aSubstrates taken from the
SLC tables database (http://www.bioparadigms.org/)

Additional File 3.13: Canonical pathways in the liver
(Liver_canonical_pathways.txt)
This file contains the canonical pathways in IPA and the corresponding –log 10 pvalues and the individual molecules that were detected as being in the list of
overrepresented genes and part of each pathway (listed in the “molecules”
column.) FDRs for the individual pathways are shown in a separate series of
rows underneath the –log 10 p-values. This table shows results utilizing the list of
differentially expressed genes in the liver.

Additional File 3.14: Canonical pathways in the duodenum
(Duodenum_canonical_pathways.txt)
This file contains the canonical pathways in IPA and the corresponding –log 10 pvalues and the individual molecules that were detected as being in the list of
overrepresented genes and part of each pathway (listed in the “molecules”
column.) FDRs for the individual pathways are shown in a separate series of
rows underneath the –log 10 p-values. This table shows results utilizing the list of
differentially expressed genes in the duodenum.
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Additional File 3.15: Canonical pathways in the jejunum
(Jejunum_canonical_pathways.txt)
This file contains the canonical pathways in IPA and the corresponding –log 10 pvalues and the individual molecules that were detected as being in the list of
overrepresented genes and part of each pathway (listed in the “molecules”
column.) FDRs for the individual pathways are shown in a separate series of
rows underneath the –log 10 p-values. This table shows results utilizing the list of
differentially expressed genes in the jejunum.

Additional File 3.16: Canonical pathways in the ileum
(Ileum_canonical_pathways.txt)
This file contains the canonical pathways in IPA and the corresponding –log 10 pvalues and the individual molecules that were detected as being in the list of
overrepresented genes and part of each pathway (listed in the “molecules”
column.) FDRs for the individual pathways are shown in a separate series of
rows underneath the –log 10 p-values. This table shows results utilizing the list of
differentially expressed genes in the ileum.

Additional File 3.17: Thyroid pathway in liver (Liver_thyroid_pathway.jpg)
Images from IPA for the TR/RXR pathway for the liver. Red shading indicates
increased mRNA amounts of the respective gene during lactation, and green
shading indicates decreased amounts of mRNA.
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Additional File 3.18: Thyroid pathway in duodenum
(Duodenum_thyroid_pathway.jpg)
Images from IPA for the TR/RXR pathway for the duodenum. Red shading
indicates increased mRNA amounts of the respective gene during lactation, and
green shading indicates decreased amounts of mRNA.

Additional File 3.19: Thyroid pathway in jejunum
(Jejunum_thyroid_pathway.jpg)
Images from IPA for the TR/RXR pathway for the jejunum. Red shading
indicates increased mRNA amounts of the respective gene during lactation, and
green shading indicates decreased amounts of mRNA.

Additional File 3.20: Thyroid pathway in ileum (Ileum_thyroid_pathway.jpg)
Images from IPA for the TR/RXR pathway for the ileum. Red shading indicates
increased mRNA amounts of the respective gene during lactation, and green
shading indicates decreased amounts of mRNA.

Additional File 3.21: RT-PCR primers (RT_PCR_primers.pdf)
Primer sequences for all genes analyzed by RT-PCR.

© Antony Athippozhy 2011
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Chapter 4
Detection of Differential Alternative Splicing in the Lactating Rat

Introduction
Lactating dams have increased energy demands. Several physiologic changes
occur in the animal to accommodate the need to provide for both themselves and
their pups. These changes include increased cholesterol synthesis [9], increased
zinc absorption [74], increased bile acid pool size [10], and increased
hydrophobicity of the bile acid pool [10]. In addition, a number of hormone
signaling pathways are altered, including those for insulin, thyroid, and leptin [19].
We have previously characterized the changes in mRNA expression in the liver
and gastrointestinal tract (duodenum, jejunum, ileum) of the lactating dam
compared to age matched virgin controls using an Affymetrix Rat Exon 1.0 ST
microarray (Affymetrix, Santa Clara, CA) [164].
In addition to changes in gene expression, alternative splicing is also a
mechanism for controlling gene function. To our knowledge, no work has been
done to characterize changes in mRNA splicing during lactation. One tool that
has been developed to characterize differences in splicing between two different
groups is the Exon Array. In contrast to traditional 3’-expression arrays, probes
in the Exon Array are designed to detect individual exons. This allows for
measurements of individual exons, and a comparison of exon expression
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between two groups relative to the corresponding gene expression allows for
identification of genes that are differentially spliced between the groups.
In spite of the minimal work done to characterize splicing within the context of the
lactating animal, the serum levels of several hormones that affect splicing are
known to be altered. Lactating rats are hypoinsulinemic [19], hypoleptinemic
[19], and hyperprolactinemic when compared to nonlactating animals. These
pathways influence PI3K signaling [37, 38, 52, 54, 57, 58, 60, 61]. Insulin
signaling can trigger differential splicing of protein kinase C β II through the PI3K
pathway and ultimately through differential phosphorylation of SRp40, a member
of the serine-arginine (SR) family of proteins which are often involved in the
regulation of alternative splicing [68]. Likewise prolactin receptor activation leads
to differential splicing of neuronal nitric oxide synthase (nNOS) in the rat anterior
pituitary cell line, GH 3 [67]. Consequently, differential alternative splicing through
differential phosphorylation of SR proteins downstream of PI3k signaling seems
likely in lactating animals.
Several methods have been developed to analyze data from exon array chips.
Two of these methods are ANOSVA [107] and MiDAS [97]. ANOSVA is a
method based on a two-way ANOVA, utilizing the factor (i.e. source of variance)
of interest and an exon effect as the two main effects. A significant interaction
term between the effect of interest and the exon is considered a positive test.
This method operates under the model y ijk =µ+α i +β j +γ ij +error, where y ijk is the
measured expression level for probe k in probeset i in experiment j, µ is a
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baseline measurement, α i is the linear contribution of probeset i, β j is the linear
contribution of the other factor, and γ ij is the interaction effect. In the presence of
differential alternative splicing, the addition of a splicing event creates a situation
where the sum of µ, αi, and βj do not fully explain the model, and the difference is
explained in the interaction term. However, problems have been reported with
this model, as an Affymetrix white paper discussing the method described that it
“did not yield good performance” but specific flaws were not discussed [165].
Also, because the test is performed for the entire gene, the method does not give
a direct measure of where the potential splice sites occur.
Another method used to detect differential alternative splicing is called MiDAS
[97]. This method utilizes “gene normalized intensities” to identify where splicing
has occurred. The gene normalized intensities are calculated as the ratio of an
individual exon’s expression to an estimate of the gene’s overall expression. If a
significant difference occurs between “gene normalized intensities” for a given
exon, then that exon may be differentially spliced. Analysis is often done by
utilizing a t-test on the gene normalized intensities [97]. In some cases, this
method has reported low validation rates, as there are several well-known
sources of false positives in exon microarrays. These include failure of a probe
to hybridize to its target cDNA, hybridization to nontarget cDNAs, and a gene not
being expressed in one of the treatment groups [97]. Because of these
problems, adequate prefiltering before analyzing the data is a necessity [97].
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We have utilized a combination of ANOSVA and MiDAS to detect differential
splicing. We have characterized differential alternative splicing in the liver,
duodenum, jejunum, and ileum of lactating rats compared to age matched virgin
controls by running ANOSVA to identify differentially spliced genes, followed by
MiDAS to identify differentially spliced exons.
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Results
ANOSVA Overestimates p-values
The physiologic state*probeset interaction p-values were plotted as histograms
for each tissue (Figure 4-2). In the absence of any significant interactions (and
under the assumptions of the algorithm, in the absence of alternative splicing),
the interaction p-values would be expected to be normally distributed. However,
histograms of the p-values show that p-values were biased toward one (1) in
each tissue, although in the ileum, there was both a bias toward zero (0) and one
(1). This indicates that the ANOSVA method is in general, overestimating the pvalues, as the expected uniform distribution of nonsignificant results was not
present. Histograms of MiDAS p-values (Figure 4.3) appeared to follow a similar
trend, but the effect was much less pronounced, since there were multiple exons
for each gene.
Number of genes that tested positive in each tissue for alternative splicing
Because low validation rates have been reported for microarray experiments,
and validation can be a time-consuming and costly endeavor, we chose a
relatively stringent cutoff at the level of ANOSVA (FDR=0.05). In three of the four
tissues, very few genes (i.e., less than 20) were detected as positives (Tables
4.1-4.3). Given that an FDR of 0.05 indicates that approximately 1 in 20 genes
are false positives, and fewer than 20 genes appear in these lists, it is plausible
that some of these genes tested positive by chance. However, the ileum
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displayed a much higher incidence of positive tests (Additional File 4.1). This is
indicative of a unique event occurring within the ileum, as all tissues were
analyzed using the same model.
UGTs Test Positive for Alternative Splicing
In both the liver and the ileum, the gene associated with the UDP
glucuronosyltransferase 1 family polypeptide a (UGT1a) tested positive for
alternative splicing. The UGT1a differ by usage of an alternative first exon. The
splicing events that tested positive by the microarray were associated with
probesets that match the alternative first exons. In the liver, probesets 6347739
and 6443473 tested positive for differential alternative splicing, while in the ileum,
no individual probesets tested positive in MiDAS, although the ANOSVA for the
gene gave a significantly low p-value. By using University of California, Santa
Cruz (UCSC) genome browser [166, 167] to align the target sequence against
the genome, we identified probeset 6347739 as being associated with the first
exon of Ugt1a7c, and probeset 6443473 as being associated with the first exon
of Ugt1a6.
Alternative Splicing of Abcg8
Initial analyses of the extended dataset prior to filtering out poorly expressed
probesets resulted in a larger number of positive tests. Within this dataset,
Abcg8 was flagged as a likely candidate for alternative splicing in the liver only
(positive at FDR<0.05; Figure 4.4). RT-PCR detected a splice variant that was
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present in lactating samples, and this variant was sequenced. (Additional File
4.2). Only one transcript variant was sequenced, although others were identified
in the RT-PCR products.
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Discussion
A Series of Events Occur in the Gastrointestinal Tract That is Unique to the
Ileum

The same algorithm was utilized to detect the possibility that lactation triggers
changes in alternative splicing in each tissue. In three of the tissues, very few
positive tests were detected. However, the ileum showed substantially more
positive alternative splicing events (89 in the ileum, less than 20 in each of the
other tissues). Although events such as alternative start site and stop site usage
would also test positive as alternative splicing events, this indicated that a unique
physiologic event was occurring in the ileum of lactating rats that was not
occurring in the liver, duodenum, or jejunum. Based on differences in serum
hormone levels reported in lactation, we had reason to hypothesize that levels of
alternative splicing in the gastrointestinal tract were altered during lactation.
Thus, changes in signaling via the PI3k/Akt pathway could affect splicing
mechanisms. However, in three of the four tissues, the number of splicing
events detected by the microarray chip was small. Alternative splicing events in
any of these tissues in the lactating animal have not been characterized
previously. Further work needs to be done to characterize what changes in the
local environment of the ileum might trigger differences in alternative splicing that
are unique to the ileum when compared to the other more proximal parts of the
small intestine and the liver.
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Abcg8 is Differentially Spliced in the Liver of Lactating Dams, but not in the
Small Intestine

Our previous analyses [5] showed that Abcg8 is differentially expressed in the
livers of lactating rats. mRNA and protein levels are significantly decreased, and
functional heterodimer was not detectable in livers of lactating dams. Initial
analyses of the microarray data for the detection of alternative splicing prior to
filtering out poorly expressed genes indicated that Abcg8 might be differentially
spliced in the liver of lactating animals. From the plots of probeset intensity, the
probesets in the liver of lactating rats show a clearly different pattern of
expression than in any other tissue or physiologic state group (Figure 4.4). We
investigated the cause of the unique expression pattern in these livers. RT-PCR
identified a transcript variant within the lactating liver samples. This variant was
sequenced and found to be missing part of exon 4, all of exons 5,- 8, and part of
exon 9. Blasting the sequence of the clone against the rat genome identified the
best match was Abcg8, with several regions having 100% identity and others
varying only by a single nucleotide mismatch or a gap. Comparing the
determined sequence against NCBI’s NM_130414 mRNA entry and NP_569098
protein entry, it was determined that this transcript most likely would not have
been able to produce functional protein. In addition to the possibility that the
transcript’s product may not have been able to form a dimer with Abcg5, this
transcript would likely not include many key features of the transporter, including
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the Walker B motif in the nucleotide binding domain where ATP is bound. This
result indicated that within the lactating liver, incomplete transcripts of Abcg8
were being formed, and these transcripts may not be able to form the functional
protein, providing further description for the lack of functional Abcg8 protein
detected in the liver of lactating dam. This, in addition to the substantially
decreased amounts of Abcg8 mRNA, suggested that control of Abcg8 levels in
lactating dams happened at least in part at the level of transcription. As we have
described in Chapter 3, loss of Abcg5/g8 requires that cholesterol be secreted
into bile through an alternative mechanism rather than through transport
mediated by the Abcg5/Abcg8 heterodimer. Abcg5 was not detected to be
differentially spliced in the same manner, but failure to produce functional Abcg8
interferes with the formation of functional heterodimer [168]. Abcg8 was
removed from the final analysis in liver due to its already low expression in liver
samples from lactating animals.

The Gene Associated with Members of the Ugt1a Family of Enzymes Shows
Differential First Exon Usage in the Microarray Data in Both the Liver and
the Ileum

mRNA associated with the Ugt1a proteins tested positive for differential
alternative splicing in the liver and ileum. The Ugt1a locus codes for a family of
proteins that differ in their amino termini, but have consistent carboxy termini.
This is accomplished through utilization of a variable first exon, followed by the
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consistent usage of exons 2-5. These enzymes are responsible for transferring
glucuronic acid to the substrate, which generally creates a water soluble,
biologically inactive product. These enzymes are important in both elimination of
endogenous substrates and various drugs. A review of many example drug
substrates can be found in Kiang et al [169].

Because the microarray makes measurements on each individual exon,
differences in the usage of the differential first exon can be identified when
testing for alternative splicing. In both the liver and the ileum, the Ugt1a locus
was identified as a site of “differential alternative splicing”, and further analyses
revealed that the detected sites were located in the alternative first exons. In the
liver, Ugt1a6 and Ugt1a7 were identified as having higher expression of the
corresponding first exon present in the lactating samples compared to controls,
while in the ileum, no forms were found differentially expressed by MiDAS, but
Ugt1a3 and Ugt1a5 appeared to have slightly decreased expression of mRNA
from the respective first exons in lactating dams (Figure 4.5). However, the
constituitive exons 2-5 did not display a change in expression. These results
suggested that drug metabolism may be altered in lactating dams. For example,
Ugt1a6 can metabolize acetaminophen. The results from Ugt1a6 were
consistent with reports of transgenic mice expressing the human UGT1A locus
having higher levels of UGT1A6 post-partum [170]. Also, Ugt1a6 mRNA and
protein have been shown to be increased in lactating rats and in rats treated with
ovine prolactin [94], indicating that our results regarding Ugt isoforms were
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consistent with previous literature. Further studies need to be performed to
elucidate how differences in Ugt levels actually influence drug metabolism.

Other Genes Detected to be Differentially Spliced and Biological Roles

Because the ileum showed a substantially higher number of splicing events
compared to the other three tissues, we chose to focus on it for further analyses.
Additional File 4.1 displays genes that tested positive in the ileum and
corresponding physiologic state*probeset_ID interaction p-values as calculated
by Partek. Angiotensin converting enzyme 2 (Ace2) showed the lowest p-value
for alternative splicing in ileum using the two-way ANOVA model in Partek
(Figure 4.6). MiDAS results, in conjunction with plotting exon intensities as a
function of chromosomal position in both groups, revealed that probeset
5728701, which maps to the 3’ end of exon 9 in the UCSC genome browser, was
a possible site of differential alternative splicing, as a drop in both groups
occurred, but the magnitude of the drop was greater in the control group. This
would indicate that proportionately fewer transcripts contained the exon in control
than lactating animals. In the duodenum and jejunum, a large decrease in
expression of the probeset was observed, but there was no statistically
significant difference in the gene normalized intensities between the groups.
These results indicate that the splicing event was unique to the ileum.
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Ace 2 catalyzes conversion of angeniotensin II into the inactive heptapeptide
Ang1-7. Active angiotensin II is responsible for triggering increased blood
pressure [171] and secretion of aldosterone, which leads to sodium retention
[172]. The degradation of angiotensin II prevents further activity, meaning that
ACE2 plays a key role in regulating blood pressure and sodium levels.
Furthermore, the heptapeptide Ang1-7 can inhibit angiotensin II activity [173].

Using BLAT [174] against the Nov. 2004 (Baylor 3.4/rn4) assembly [175] to map
the location of probeset 5728701’s target sequence in the UCSC genome
browser did not reveal any ESTs for Ace 2 that were spliced in the corresponding
region. The most likely explanations for the results observed are that the probe
hybridizes poorly, as marked by the large decrease in intensity relative to other
probes in the same gene in all parts of the small intestine, or that the splicing
event was real and was unique only to the ileum. The region corresponding to
probeset 5728701 matches the mRNA refseq entry NM_001012006 from
nucleotides 1301 to 1326. This was consistent with amino acids 434-442 in the
translated protein, which can also be viewed in the NCBI refseq entry
NM_001012006 or in the protein entry NP_001012006. This region was included
with the peptidase region from amino acids 22-612, but was not associated with
any active sites within the protein entry, which map to amino acids 345-348,374375,378,382,401-402,449,503,505,512, and 515. Consequently, if this splice
form interfered with function of the full protein, it would likely be from a
conformational change through missing residues near the active sites; the
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closest active site was threonine 449. Because this splice form retains its active
sites and its transmembrane domain, the splice variant may still be biologically
active, however this requires independent verification.

DAVID [105] was used to identify similarities amongst genes that were
differentially alternatively spliced in the list of 89 genes detected in the ileum.
Amongst these, four members of the renin angiotensin (p=5.4X10-4) pathway
were detected, including the previously mentioned Ace2. Figure 4.7 shows the
KEGG renin angiotensin pathway, as displayed from within DAVID. Members
marked with stars were members of the renin angiotensin pathway. The other
three members were alanyl (membrane) amino peptidase (Anpep), leucyl/cystinyl
peptidase (Lnpep), and membrane metallo endopeptidase (Mme).

Seventeen members of the SP_PIR_Keywords group “alternative splicing” tested
positive for differential alternative splicing (p=4.1X10-3) (Table 4-4). Amongst
these was the Ugt1a locus, which produces different proteins based on usage of
an alternative first exon and is discussed in detail above. These are proteins that
have been previously associated with alternative splicing.

In the liver, probesets associated with Ugt1a6 and Ugt1a7 were detected as
differentially spliced. This suggested possible differences in improved ability to
conjugate phenols, such as acetaminophen. In the rat, Ugt1a6 and Ugt1a7 are
co-regulated through Ahr [95], suggesting that these results may have been a
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response to the same mechanism. However, this result is not directly
transferable to humans, as humans do not express Ugt1a7 in the liver [176]. This
result was consistent with previous reports that Ugt1a6 mRNA and protein ares
increased during lactation and in response to prolactin [94].

Using a network drawn around Ahr in Ingenuity Pathways Analysis (Ingenuity
Systems, www.ingenuity.com), we found that four genes differentially expressed
in the liver would be influenced by Ahr. Two changes were consistent with
increased Ahr activity: increased Cyp1a1 [177] and decreased Serpina7 [178].
The other two changes that would be influenced by Ahr activity occured in the
direction opposite of the expected change. Hmgcr [179] transcription was
increased [164] and Phophoenolpyruvate carboxykinase 1 (Pck1, also known as
Pepck), a key regulator in gluconeogenesis, transcription was decreased [178].
The inconsistent changes were easily explained by the change in the lactating
rats’ metabolic state, as discussed in Chapter 3.

RT-PCR Validation of Alternative Splicing Events

The following factors should be considered when determining which alternative
splicing events are likely true positives. First, does the exon in question show a
substantial difference in intensity and gene normalized intensity from the other
exons? Low variance across the measurement could lead to a statistically
significant result, but if the cause of that low variance was not a direct result of
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the treatment, then the answer would be a false positive. Relative expression of
the exon to the other exons in the gene may be an indication of actual alternative
splicing, since it should be expressed at a lower level than constitutively
expressed exons, although probe affinity should be accounted for when
comparing across exons.

Another factor to take into account when choosing genes for which to validate
splicing events is the presence of existing known splicing events [97]. The
existence of known exons indicates that the transcript variant in question exists,
and the only thing needed to be validated is the relative level of transcripts in
each treatment. In some cases, the experimenter may be interested in novel
splice variants or the animal model’s transcriptome has been poorly sequenced.
In these cases, the experimenter may need to consider if consensus or
alternative acceptor and donor sites exist within the sequence. The donor and
acceptor sites indicate the 5’ and 3’ ends of the splice site, respectively [180]. If
the region of interest is on the 5’ or 3’ end of the message, alternative initiation
and poly adenylation sites may need to also be considered.
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Conclusions

The results of this study are consistent with previous findings that Ugt1a6
expression is increased in the liver of lactating dams. Our results indicated that
Ugt1a7 may be regulated in a similar manner. We have detected an mRNA
transcript variant of Abcg8 in the liver that further indicates that control of the
levels of functional Abcg5/Abcg8 heterodimer are controlled at the level of
mRNA. Our results also suggested possible differential alternative splicing of
four members of the renin-angiotensin pathway, especially Ace2, which is key in
inhibiting the renin-angiotensin pathway. Further work needs to be performed in
order to validate exactly how splicing events are regulated in the gastrointestinal
tract in lactating animals when compared to virgins. For example, the ileum was
more responsive to changes in alternative splicing than the liver, duodenum, or
jejunum. Current methods for identifying differential alternative splicing,
particularly ANOSVA and MiDAS need to be refined to be applicable to the
microarray dataset, as p-values did not form a uniform distribution for nonsignificant tests, indicating that assumptions within the model were violated. We
have specified a minimal difference filter in order to attempt to rectify some of the
false positives. Finally, RT-PCR using primers flanking probable splice sites for
genes that were strong candidates for differential splicing, such as Ace2 in the
ileum needs to be performed. Validating the RT-PCR results will describe how
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well the additional filters work, as well as provide insights regarding the biology of
the lactating animal, as differential splice variants may play different biological
roles.
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Materials and Methods
Animals
The data used here were obtained as described in Chapter 3 and published
recently [164]. Briefly, sixteen Sprague-Dawley rats at day 10-11 of lactation and
sixteen age matched virgin controls were obtained from Harlan (Indianapolis, IN).
All animals were sacrificed at 16 h (10 h of light on a 12 hour light/dark cycle; 4
PM), and the liver, duodenum, jejunum, and ileum removed for total RNA
extraction from each tissue. The integrity of all RNA samples was verified by an
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Animal
protocols were conducted in accordance with the National Institutes of Health
Guidelines for the Care and Use of Laboratory Animals and were approved by
the Institutional Animal Care and Use Committee of the University of Kentucky.
Each rat was assigned to one of four pools within the respective physiologic state
(treatments; four control pools and four lactating pools.) Pooled RNA samples,
consisting of the RNA from the four rats within the same group, were created for
each tissue, with individual rats composing the pools consistent across tissues.
resulting in the use of 32 chips (4 tissues X 2 “treatments” X 4 pools). Samples
were prepared and processed according to the manufacturer’s instructions by the
University of Kentucky Microarray Core Facility (Lexington, KY)
Data Filtration
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The data were filtered in order to reduce the risk of false positives. Affymetrix
Expression Console software (Affymetrix, Santa Clara, CA) was used to perform
the Robust Mutichip Averaging (RMA) [98, 99] algorithm on each tissue
separately on the “Core” dataset. For example, the eight chips associated with
the liver were analyzed at the same time, but were analyzed separately from the
eight chips associated with the duodenum. During these calculations, Detection
Above Background (DABG) values were calculated. A DABG of less than 0.01
was considered a positive test, and probesets (treated as exons for the purposes
of the calculations) with DABG values of less than 0.01 were considered present
on the respective chip. If a probeset was present in at least three of four chips in
control or lactating groups, the exon was considered present in that group. If a
probeset was not considered present in both groups, it was removed from
analysis for determining differential splicing. A column determining whether a
given probeset was present for a given group (control or lactation) (in which case
a value of “1” was assigned) or absent (in which case a value of “zero” was
assigned) was added to the spreadsheet. A second presence call was
generated with a value of “1” indicating that the probeset was present in at least
one group, and a value of “0” indicating the probeset was present in neither
group. This was repeated for probeset intensity, where a cutoff of the log2 RMA
intensity was 4 rather than applying a DABG cutoff, and the presence/absence
assignment was done in the same way. The Affymetrix Rat Exon 1.0ST
annotation file (raex-1_0-st-v1-na30.rn4) was also used to identify genes that
have been characterized as risks of cross-hybridizing to nontarget cDNAs. Any
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exon identified as a risk was removed from analysis. Affymetrix has identified
probesets that may have issues with cross-hybridizing to cDNA other than the
intended target. In the Affymetrix annotation file, a value of “1” in a column
labeled “Crosshyb_type” is assigned to probesets that are not likely at risk to
cross-hybridize to nontarget cDNA. Any value other than “1” in the annotation file
under the column “Crosshyb_type” was determined to be a risk for crosshybridization. In our dataset, a column containing a “1” for the row if the probeset
in question was determined not likely to cross-hybridize and a “0” if the probeset
was likely to cross-hybridize was created. The product of the three
presence/absence calls was used to determine if a probeset was present or
absent. Presence calls were made for each group and overall. A gene was
considered present overall if both the DABG cutoff and the intensity cutoff
indicated half of the probesets were present in both control and lactation.
JMP Genomics (SAS Institute Inc, Cary, NC) was used to summarize each of the
probeset_IDs into transcript clusters (genes). The sum of present exons in
control or lactating samples were calculated for each gene. If 50% of the exons
in a given gene were not expressed in either control or lactation, the gene was
removed from analysis. An intensity cutoff at the gene level was applied in a
similar manner to the intensity cutoff applied at the exon level. If a gene
expressed an intensity of at least four in three of the four chips within a group, it
was considered present for the group; otherwise, it was considered absent for
that group. This time, a gene needed to be present in both groups to be
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considered present overall. These steps were repeated for each tissue.
Presence/absence calls were used to generate a text file that contained a list of
probesets to be used in the final analysis.
Detection of Differentially Spliced Genes
Affymetrix .CEL files were uploaded into Partek Genomics Suite ©2011 (Partek
Incorporated, St. Louis, MO) [181], and the RMA algorithm was utilized to treat
the data. After implementing the RMA algorithm, a list of probesets to be utilized
according to the filtration procedures described above was used to filter the
dataset. Each tissue was loaded separately into Partek, and the RMA algorithm
was performed separately for each tissue. Partek was then used to run a two
way ANOVA treating physiologic state and exon as the two main effects. The
physiologic state*exon interaction term was used as an estimate for the likelihood
that a gene was differentially spliced within lactating animals compared to virgin
controls. A false discovery rate (FDR) was calculated by Partek and a value of
0.05 was used as a cutoff for a positive alternative splicing test in each tissue.
Detection of Differential Splice Sites
RMA values of exon and gene intensities from the RMA algorithm performed in
the Affymetrix Expression Console software was used to calculate “gene
normalized intensities”. The gene normalized intensity was defined as the RMA
calculated intensity value of a probeset_ID divided by the intensity value of the
corresponding gene level intensity. A t-test for these values with respect to
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physiologic state was performed for each exon within a gene that tested positive,
and this procedure was repeated for each tissue. A p < 0.01 in MiDAS was
considered a positive test for differential splicing of a given exon. The t-tests
were performed in Microsoft Excel (Microsoft Corporation). Graphs of exon level
intensities as a function of treatment and exon for genes that tested positive were
also investigated in Partek. Because low variance appeared to be an issue in
some positive tests, we also specified that a minimal difference of 0.5 on a log 2
scale between mean exon intensities be present. The minimal difference filter
would filter out situations where poor probe expression occurred but failed the
presence/ absence filter. There were other cases in which the difference
between exon expression appeared minimal when the data were displayed
graphically (Figure 4-1), and consequently only positive tests that also displayed
a large difference (0.5 on a log 2 scale) were considered positive for the purposes
of detecting the locations of potential splice sites.
RT-PCR and Sequencing of an Abcg8 Splice Variant
RT-PCR was performed on a Roche Light Cycler 280 instrument (Roche Applied
Sciences, Manheim, Germany). The forward primer for Abcg8 was
ATGGCTGAGAAGACCAAAGAGG, and the reverse primer was
ATCATTGTCCTCAGTCGGGCTC. Samples were taken from the original RNA
samples from the liver used for the microarray. RT-PCR products were
separated on an agarose gel. A single RT-PCR product was extracted that was
detected in the lactating sample, and this product was sequenced at MWG
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biotech (Huntsville, AL). This portion of the study was carried out by Dr.
Tianyong Zhao in our laboratory.
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Figures

Figure 4.1: A sample case of low variance leading to a likely false positive in
MiDAS. Lnpep tests positive by ANOSVA, and three probesets test positive at
p<0.01 in MiDAS. Although these probesets have low p-values due to low withingroup variance, validation of an actual splicing event and its biological relevance
at these sites would be difficult. The figure was extracted from Partek genomics
suite, with probesets that test positive for MiDAS being circled. The circled
exons were removed from the list of positive exons if a minimal difference of 0.05
113

between probeset intensities was enforced. Intensities (right axis) are plotted as
a function of chromosome position (bottom axis). Chromosome number is listed
on the left axis. The two Refseq transcripts are listed across the top
(NM_001113403 and NM_133574), with boxes representing individual exons.
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Figure 4.2: Histograms of alternative splicing p-values calculated by Partek.
Values show a bias toward p=1.0, suggesting that underlying assumptions within
the model are violated. On the x-axis are p-values and the y-axis represents the
number of genes at the corresponding p-value. A. Liver, B. Duodenum, C.
Jejunum, and D. Ileum. The darker shaded region represents p<0.01.
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Figure 4.3: Histograms of MiDAS p-values for probesets detected as present on
the microarray chips in the respective tissue (A. Liver, B. Duodenum, C.
Jejunum, and D. Ileum). On the x-axis are p-values and the y-axis represents
the counts of probesets at the corresponding p-value. In the liver, duodenum,
and jejunum, an upward shift appears toward p=1, indicating that nonsignificant
results were not uniformly distributed, suggesting some underlying assumptions
regarding the MiDAS algorithm have been violated. Darker shaded regions
represent p<0.01.
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C

Figure 4.4: Abcg8 probeset expressionin A. Liver, B. Duodenum, C. Jejunum,
and D. Ileum. Data compare probeset expression in lactation (blue line) against
control (red line) before setting filters to remove absent exons and genes. The
liver responds substantially differently to lactation at the level of individual
probesets than the other tissues. This has been validating using RT-PCR. .
Intensities (right axis) are plotted as a function of chromosome position (bottom
axis). The left axis lists the chromosome number. Along the top is the NCBI
refseq entry for Abcg8, with boxes representing individual exons.
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A

B

Figure 4.5: Probeset expression of the Ugt1a locus in liver (A) and ileum (B). In
the liver, genes that tested positive by MiDAS at p<0.01 are circled. In the ileum,
no probesets passed this test. In the liver, exons associated with Ugt1a6 and
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Ugt1a7 show increased expression during lactation (blue line) compared to virgin
controls (red line).
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Figure 4.6: Ace2 probeset expression in duodenum (A), jejunum (B), and ileum
(C). Individual probeset intensities are plotted as a function of chromosome
position as indicated by Partek. Each tissue displays a substantially lower
expression for probeset 5728701, but only in the ileum was significant differential
relative expression detected between control (red line) and lactation (blue line).
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Figure 4.7: The renin angiotensin system from KEGG [126, 160, 161] as
displayed in DAVID. Stars denote specific enzymes detected as differentially
alternatively spliced within the pathway. Using the list of genes differentially
alternatively spliced in the ileum, the renin angiotensin pathway displays a pvalue of 5.4X10-4.
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Tables

Table 4-1: Genes detected to be differentially spliced in the liver of lactating
animals

Gene

# of

Transcript

Symbol

probesets Cluster ID

RefSeq

alt splicing p

Bhmt

7

7202449 NM_030850

1.07E-08

Cdc42

8

7292247 AF205635

1.79E-08

Cpa1

9

7252157 NM_016998

1.07E-07

Gck

13

7127894 NM_012565

1.55E-07

Lss

26

7221620 NM_031049

1.63E-06

Ugt1a

23

7357340 NM_201425

1.19E-05

Slc6a13

14

7258065 NM_133623

2.59E-05

6

7089781 NM_012531

3.64E-05

Comt

ANOSVA was utilized to identify genes that were likely differentially spliced with a
cutoff of an FDR of 0.05. Bhmt: Betaine-homocysteine methyltransferase; Cdc42:
cell division cycle 42; Cpa1: Carboxypeptidase A1; Gck: glucokinase; Lss:
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Lanosterol synthase; Ugt1a: UDP glucuronosyl transferase 1 family; Slc6a13:
Solute carrier family 6 member 13; Comt: Catechol-O-methyltransferase. “Gene
symbol” is the NCBI official gene symbol for the respective transcript, “# of
probesets” indicates the number of probesets associated with the transcript,
“Transcript Cluster ID” indicates the Affymetrix transcript cluster ID associated
with the transcript, “RefSeq” identifies the Refseq entry for the corresponding
transcript, and “alt splicing p” indicates the interaction p-value between probeset
ID and physiologic state effect given by Partek.
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Table 4-2: Genes were detected to be differentially spliced in the duodenum
of lactating animals.

Gene

# of

Symbol

probesets Cluster ID

Reg1a

Transcript

6

RefSeq

alt splicing p

7255179 ---

9.19E-10

Epb4.1l3

28

7358708 NM_053927

3.57E-08

Ppap2a

7

7189673 NM_022538

1.36E-06

Slc34a2

15

7126150 NM_053380

1.48E-06

7

7184989 NM_054009

1.77E-05

Ctrl
Ptprh

14

7028616 D45413

1.95E-05

Abcb9

12

7098148 NM_022238

2.87E-05

Fbxo8

8

7150879 ---

4.50E-05

12

7240317 ---

7.32E-05

Atf2

ANOSVA was utilized to identify genes that were likely differentially spliced with a
cutoff of an FDR of 0.05. Reg1a: Regenerating islet derived alpha 1; Ebp4.1l3:
Erythrocyte membrane protein band 4.1-like 3; Ppap2a: Phosphatidic acid
phosphatase type 2A; Slc34a2: Solute carrier family 34 member 2; Ctrl:
Chymostrypsin-like; Ptprh: Protein tyrosine phosphatase receptor type H; Abcb9:
ATP-binding cassette subfamily b member 9; Fbxo8: F-box protein 8; Atf2:
Activating transcription factor 2. Column headings are as used in table 4.1.
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Table 4-3: Genes detected to be differentially spliced in the jejunum of
lactating animals.

Gene

# of

Transcript

Symbol

probesets Cluster ID

alt splicing
RefSeq

p

Acta1

7

7186461 NM_019212

6.10E-09

Alpi2

15

7357124 NM_022680

3.82E-08

LMO7

31

7134690 NM_001001515

4.38E-06

Maob

16

7373289 NM_013198

2.09E-05

Ppap2a

7

7189673 NM_022538

4.01E-05

Tpm4

8

7149580 NM_012678

7.02E-05

ANOSVA was utilized to identify genes that were likely differentially spliced with a
cutoff of an FDR of 0.05. Acta1: actin alpha 1, Alpi2: Alkaline phosphatase 3;
LMO7: Lim domain 7; Maob: monoamine oxidase b; Ppap2a: Protein tyrosine
phosphatase type 2A; Tpm4: Tropomyosin 4. Column headings are as used in
Table 4.1.
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Table 4.4: Genes found in the “alternative splicing” Sp-Pir keywords
category.

Transcript_Cluster_ID

Gene Name
ATPase, Ca++ transporting, plasma

7314252

membrane 1

7137113

ERO1-like (S. cerevisiae)
ST6 beta-galactosamide alpha-2,6-

7094780

sialyltranferase 1
UDP glucuronosyltransferase 1 family,
polypeptide A2; UDP glucuronosyltransferase
1 family, polypeptide A5; UDP
glycosyltransferase 1 family polypeptide A3;
UDP glucuronosyltransferase 1 family,
polypeptide A6; UDP glucuronosyltransferase
1 family, polypeptide A9; UDP
glycosyltransferase 1 family, polypeptide A8;
UDP glucuronosyltransferase 1 family,
polypeptide A7C; UDP
glucuronosyltransferase 1 family, polypeptide

7357340

A1

7070578

acetyl-coenzyme A carboxylase alpha

7083901

archaelysin family metallopeptidase 2

7085242

casein kinase 1, delta
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7292247

cell division cycle 42 (GTP binding protein)

7353844

interleukin 1 receptor-like 1

7146425

neuregulin 1

7160039

Optineurin
phosphatidylinositol binding clathrin assembly

7033968

protein

7192686

phospholipase D1

7289791

sterol carrier protein 2

7091588

synaptojanin 1

7347403

transcription factor 12

7346991

tropomyosin 1, alpha

Transcript_Cluster_ID refers to the Affymetrix transcript clusters that identify
each gene on the exon array, and gene name identifies the genes by name.
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Additional File 4-1: Differentially_spliced_genes_ileum.txt. ANOSVA was
utilized to identify genes that were likely differentially spliced with a cutoff of an
FDR of 0.05. Column headings are as used in Table 4.1. Gene assignment is a
detailed description of the full name of the gene, and contains the refseq entry
and gene symbol. Given in .txt format.

Additional File 4-2: Abcg8_sequence.txt Sequence of both the full Abcg8
transcript and the detected splice variant. Given in .txt format.
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Chapter 5
Discussion, Additional Studies, and Conclusions
Cholesterol Biosynthesis is upregulated at the mRNA level in lactating
dams
Analysis of the rat exon array data revealed several changes at the mRNA level
that aid in defining the physiology of the lactating rat. Fisher’s exact test in
Ingenuity Pathways (IPA) (Ingenuity Systems, www.ingenuity.com) identified
pathways that were altered at day 10, 16h lactating rats when compared to virgin
controls. The most evident change was increased mRNA from genes in the
cholesterol biosynthetic pathway. Lactating rats need cholesterol both for
secretion into the milk as well as to account for the increased production of bile
acids [10]. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (Hmgcr), the rate
limiting step of cholesterol synthesis was upregulated in the liver, duodenum, and
ileum. This was consistent with early data demonstrating increased cholesterol
synthesis in the liver and small intestine [9, 111], and increased Hmgcr activity in
the liver during lactation [86, 112]. As the cholesterol biosynthetic genes are
collectively controlled by sterol response element regulatory element binding
protein 2 (Srebp-2), a very likely mechanism for increased mRNA production of
the cholesterol biosynthetic enzymes was increased Srebp-2 activity.
As the cholesterol biosynthetic genes are all controlled by the transcription factor
Srebp-2, the activity of Srebp-2 in hepatocytes, enterocytes, and mammary
epithelial cells could prove useful in characterizing how gene expression is
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controlled during lactation. As there is some overlap between targets of the
Srebp proteins [87], the activities of Srebp-1a and Srebp-1c should also be
investigated. In addition, Srebp-1a and Srebp-2 can form a heterodimer, and
activity of the heterodimer may also be relevant in the tissues studied [182, 183].
It has been proposed that in the lactating mammary gland, exposure to prolactin
activates Akt, which in turn results in increased amounts of nuclear Srebp-1c
[184].
Nuclear amounts of Srebp-1a, Srebp-1c and Srebp-2 can be determined by
Western analysis of nuclear extracts of the tissues of interest [185] (in this case
the hepatocyte and enterocytes from each part of the small intestine.) Srebp-1c
has also been specifically identified in the nuclear extracts of rat hepatocytes by
Western blot [186].
Slc39a4 shows increased mRNA in the gastrointestinal tract of lactating
dams
In addition to utilizing pathway analysis through Ingenuity Pathways, genes were
grouped according to where in the gastrointestinal tract they display differential
gene expression. The zinc transporter Slc39a4 was in the list of genes
upregulated in the liver, duodenum, jejunum, and ileum.
Increased Slc39a4 is consistent with reports of increased zinc uptake during
lactation in rats [76] and humans [73, 74]. As Slc39a4 is the major, although not
only route through which zinc is absorbed in the small intestine [132], its
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increased expression during lactation provides a likely mechanism for increased
zinc absorption.
Here, we hypothesize that increased expression of active Slc39a4 on the apical
domain of enterocytes is responsible for the improved zinc absorption observed
during lactation. First, if the increase in Slc39a4 is leading to increased
absorption, then the increase is likely happening at the level of protein as well,
and this should be detectable on the apical membrane of enterocytes by Western
blot and immunohistochemistry [187]. Because increased mRNA levels were
detected in the microarray, it is worth detecting if the relative amounts of Slc39a4
protein are consistent with the level of gene expression detected in the
microarray. Under conditions of sufficient zinc concentration, Slc39a4 is rapidly
degraded. Therefore, it would be important to analyze levels of the protein
throughout the day in order to detect if and when protein levels are altered. In
addition, because intracellular zinc concentration regulates stabilization of
Slc39a4 mRNA and protein, dietary intake of could be monitored in order to
compare presence of Slc39a4 protein relative to the amount of zinc consumed in
the diet.
The ileum expresses increased differential alternative splicing in lactating
animals compared to the liver, duodenum, and jejunum
Utilization of a two-way ANOVA for probeset effect and physiologic state effect in
Partek (Partek Incorporated, St. Louis, Missouri) resulted in detection of a much
higher number of positive tests for the interaction term in the ileum (89) than in
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the liver, duodenum, and jejunum (less than 20 in each tissue). A positive test
was indicative of differential alternative splicing, suggesting that regulation of
differential splicing differs in the ileum relative to the other tissues. Currently, we
do not have an explanation regarding what could be regulating differential
splicing in the ileum.
The models for Analysis of Splicing Variance (ANOSVA) and Microarray
Detection of Differential Alternative Splicing (MiDAS) overestimate p-values
Histograms of p-values for both ANOSVA in Partek and MiDAS indicated a bias
toward p-values at one (1), rather than p-values being uniformly distributed when
not significant. This bias has been indicated in the literature [109] and suggested
that the models do not accurately reflect the data. We propose the following
workflow to evaluate the current existing methods for differential analysis of
alternative splicing.
Considering that both linear models (ANOSVA and MiDAS) appear to
overestimate p-values, as shown by our own data and reported elsewhere [97,
109], perhaps a parametric statistical model is not optimal for identifying locations
of alternative splicing. Regarding non-parametric tests, a Rank Product
approach has been applied, but it is computationally demanding at the gene level
[109]. In addition, although corporate software such as JMP Genomics and
Partek allow for some filtering steps to be readily applied, such as specifying a
metaprobeset file which defines which of Affymetrix’s confidence levels are used
and setting a minimal intensity filter, other filtering steps need to be applied
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manually. For example, Affymetrix suggests that probesets with intensities that
are higher than the constitutively expressed exons are likely cross-hybridizing
with cDNA other than the expected target [97]. Validation rates through RT-PCR
in published literature range from less than 50% [188] to above 80% [110] . This
clearly indicates the need for effective filtering to remove genes that appear to
test positive for various reasons, but are not differentially alternatively spliced.
Note that the phrase “differentially alternatively spliced” is used loosely, as
calculations are based on a measurement of exon intensity relative to gene
intensity. Consequently, events such as alternative transcription start sites and
polyadenylation site usage will also be detected as “alternative splicing”.
A front end package that allows the user to readily apply various filtering
algorithms as well as run a variety of statistical measures for differential
alternative splicing would prove very useful. We propose the following workflow
to integrate the existing methods for detection of alternative splicing into one
package (Figure 5.1). It has been proposed that utilizing multiple methods and
selecting the overlapping region of significant genes reduces the risk of false
positives [109], so providing a package that reports the results from these tests
and is able to generate a Venn Diagram of the overlapping regions of different
tests could prove useful. Although software such as JMP and Partek exist, these
software packages tend to rely on an ANOVA model to detect differences in
differential alternative splicing.

135

The first step to analyzing the microarray alternative splicing data is allowing the
software to access the data. There are two possible situations in which an
investigator may wish to import the data. In the first case, the investigator has
raw files directly following analysis of a dataset. In the second case, the
investigator has already converted the data into a workable format (for example,
by running RMA) and simply wishes to import the data as a spreadsheet. In the
first case, various options for background correction, normalization, and
summarization should be available. Note that the option to not summarize the
data, but rather work with the probe level data should be available in case the
experimenter wishes to work directly from this data [189]. It is important that we
include options for RMA when importing (RMA background correction, quantile
normalization, and median polish) although other options may be included such
as median normalization, and Tukey’s biweight for summarization. Note that
separate code would probably need to be written for each platform when
importing raw data files, as each company uses its own file format.
Consequently, it may be simpler to assume that the experimenter has the data
already transformed and ready to be analyzed in a .txt format, in which case the
data can be input as a large matrix. In order to perform all of the previously
described algorithms, data need to be available at the probe level, probeset (or
exon) level, and gene level, meaning three datasets ultimately need to be input,
in addition to a file that relates the multiple datasets. For Affymetrix datasets, this
is the cel design file (cdf), but a table with three columns (probe identifier,
probeset (or exon) identifier, and gene identifier) should be sufficient and readily
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available with a small amount of work for most experimenters on most platforms.
Also, it should be worthwhile to note that information other than expression
measurements may wish to be imported, such as DABG p-values for Affymetrix
datasets for the purposes of filtering out poorly expressed probesets. When
importing, investigators should be asked which values are associated with
microarrays, which microarrays are associated with respective treatment groups,
and which columns include other data.
Filtering data is an essential step in removing false positives, as nearly all
methods for detecting differential splicing events run into similar problems with
genes that are poorly expressed in a single group, exons that are poorly
expressed in all groups, and probes that cross-hybridize. Affymetrix has a series
of recommended filtering procedures [97], but finding software that readily
applies all of the available filters is difficult. Through spreadsheet manipulation,
the filters can be applied in JMP Genomics (SAS Institute Inc., Cary NC) or Excel
(Microsoft Corporation), but a streamlined approach has not been taken for many
of the possible filters. Filtering out genes that are poorly expressed in either
group, exons that are poorly expressed in all groups, and probesets that are
likely to cross-hybridize are all essential [97]. Presence/absence calls can be
made based on a value in a column being greater than or less than a specified
number. For example, one could make a first set of presence/absence calls
under the conditions where if intensity for a given exon on a chip>3, then that
exon on that chip is present; otherwise the exon is absent. We could do the
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same for DABG values (if DABG<0.05 then present, otherwise is absent). The
“cross-hyb type” column in the Affymetrix annotation files indicates whether or
not a probe is predicted to cross-hybridize with non-target cDNA. If cross-hyb
type does not equal one (which is defined as not likely to cross-hybridize to nontarget cDNA), then an absence call can be made for that probe on all chips,
indicating that the respective exon is to be filtered out. Affymetrix’s
recommendation for applying a presence/absence call for gene level data is
whether 50% of the exons are present, so a presence/absence call could be
made from the probeset level data accordingly. Under normal circumstances, a
gene should be removed if it is not expressed in any group, and a probeset/exon
should be removed if none of the groups express the probeset/exon.
Both JMP Genomics and Partek rely on a two-way ANOVA method for detection
of differential splicing analogous to the ANOSVA method. However, other
methods exist including MiDAS [97], FIRMA [108], PECA-SI [189], and analysis
of the rank products of splicing indices or intensities [109]. R-code exists for
these methods, and given the open-source nature of R, these codes could be
edited with credit to the original authors [108, 109, 189]. Ideally, software would
ask the investigator which method should be applied and then analyze the
corresponding method. Like many other steps, clever spreadsheet manipulation
makes these methods technically available using other software, although code
to run these methods has not been specifically written for the spreadsheet
management software. However, organizing the methods so that they are
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readily executable would be a useful tool. Following analyses, spreadsheet
software or the proposed software should be able to generate a Venn diagram of
genes that test positive at various cutoffs (either raw p-values or FDR correcting
methods can be used) from the various output files. Note that many of these
steps are computationally intensive, so managing how memory is used could
become an issue. Ideally, this should give a mechanism for readily comparing
the large number of methods for detecting alternative splicing that exist. The
overall workflow can be found in Figure 5.1.
An alternative transcript was detected for Abcg8 in the lactating liver
Abcg8, part of a heterodimer that transports cholesterol into bile, shows
decreased mRNA in the liver of lactating rats [93, 164], and functional Abcg8
protein is not detectable in the hepatocytes of lactating dams [93]. In preliminary
analysis of the alternative splicing dataset, Abcg8 was identified as a likely
candidate for differential alternative splicing in the liver of lactating dams. We
therefore ran RT-PCR on the liver samples and isolated a band that was unique
to a clone in lactating liver. Sequencing revealed that a region that begins in part
of exon four and ends in part of exon nine was spliced out in the splice variant.
This further indicated part of the control of Abcg5/Abcg8 activity in the liver in
lactating rats is controlled at the mRNA level.
Possible differential alternative splicing in the renin-angiotensin system
was detected in the ileum
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Analysis of the list of genes that tested positive in the ileum by DAVID [105]
resulted in identification of the renin-angiotensin as being a candidate for
differential regulation in lactation through alternative splicing. Of the four genes
detected to be differentially alternatively spliced in Partek, one, angiotensin
converting enzyme 2 (Ace2) had the lowest alternative splicing p-value amongst
any gene in the dataset. Ace2 is important in inhibiting the renin-angiotensin
pathway, so validating the presence of the detected splice variant, and
characterizing if it has altered function would be useful in describing the reninangiotensin pathway in the lactating rat.
Future work: Characterization of Differences in Gene Expression in the
liver Throughout Pregnancy and Lactation
Our present work identified differences in gene expression in the liver and small
intestine of lactating rats compared to age matched virgin controls at day 10
postpartum, 16 h. This only characterizes the difference in gene expression
relative to controls at one specific time point. One important question would be
how the changes identified in lactating rats at this time point differ from changes
at other time points. For example, our laboratory has identified that day 10, 16h
is the first point at which Cyp7a1, the rate limiting step for bile acid synthesis,
shows a statistically significant increase in mRNA expression [10]. However, we
have noted a number of physiologic differences regarding expression of hepatic
bile acid transporter in early (day 2 postpartum) lactation [82]. Taking samples
across several stages in lactation and pregnancy would allow an investigation for
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when changes in gene expression begin and end. If trends in gene expression
are associated with specific pathways or transcription factors, this would also
allow characterization of the roles of these pathways during lactation. We
propose measuring gene expression through microarray at the following time
points: virgin (16 h), early pregnancy, late pregnancy, early lactation (day 2
postpartum, 16 h), middle lactation (day 10 postpartum, 16h), and late lactation.
Following the previous pooling scheme of four replicates per group and four
individual rats composing a single replicate may lead to an excessive number of
required rats (4 rats X 4 replicates X 6 groups = 96 rats). The absence of a
pooling scheme would result in higher variance amongst individuals, meaning
that the statistical power would be based solely on the four replicates. A possible
compromise would be to reduce the number of rats pooled in a sample to three,
requiring a total of 72 rats for the entire experiment. We chose to focus on the
liver because of its role in regulating bile acid synthesis, metabolizing
xenobiotics, as well as being a major site of cholesterol biosynthesis. Similar
experiments have been performed in the mammary gland of pregnant and
lactating mice [184, 190]. If we choose to only analyze a specific pathway, such
as the cholesterol biosynthetic pathway, a small custom chip or nanostring
experiment would be more efficient, and statistical power would be improved by
reducing the number of genes queried.
A one-way ANOVA model would be used for the purposes of determining
statistical significance of each gene, with time being treated as a class variable.
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The overall ANOVA would initially be fitted to an FDR of 0.2. Genes that pass
the initial test will need to be tested for pairwise comparisons between the
respective time points. To simplify comparisons, we would only consider the
differences of each time point relative to the virgin controls. This reduces the
number of pairwise comparisons performed for each positive testing gene from
15 to 5. We currently propose a significance cutoff of p<0.0020 for the statistical
contrasts, but both this value and the FDR may need to be adjusted based on the
size of the list of significant genes. (The p-value for contrasts within a gene is
based on a modification of the Bonferroni procedure at α=0.01, as
0.01/5=0.0020). If the list is not sufficiently large, then pathway analysis
becomes difficult.

Statistical pattern matching could then be used to assign

genes to groups. Each time point other than the virgin time point could be
assigned to increased, no detectable change, or decreased relative to virgins for
each gene. For the purposes of pattern matching, the pairwise comparison p
value cutoff may need to be relaxed to p<0.05, but only if the gene was
previously defined as differentially expressed. This is caused by the fact that a
false negative would lead to assignment of a gene to a separate group.
Characterization of these groups should give an indication as to when genes
increase and decrease expression during pregnancy and lactation, and could
lead to identification of signaling pathways that mediate changes in gene
expression.
Conclusion
142

We showed through microarray studies increased mRNA of cholesterol
biosynthetic genes in the liver and small intestine and a likely mediator of
increased zinc uptake (Slc39a4). We propose that increased Srebp activity,
particularly Srebp-2 is involved in the increased cholesterol synthesis detected in
the liver and small intestine of lactating dams. In addition, we propose that the
difference in expression in Insig in the small intestine and Scap in the liver
causes the more dramatic increase in cholesterol synthesis in the liver relative to
the small intestine. Further work needs to be done to elucidate the mechanisms
regarding how these changes in mRNA influence the physiology of the lactating
animal. In addition, we have proposed candidates for differential alternative
splicing between lactating animals and virgin controls and have detected a splice
variant of Abcg8 in the livers of lactating animals. We also identified a possible
splice variant for Ace2 in the ileum that requires verification. Depending on the
function of the splice variant, the Ace2 variant may influence sodium absorption
and blood pressure in the lactating animal. A number of additional studies can
be performed, both to further characterize alternative splicing in more detail, and
to elucidate how the detected changes in gene expression and alternative
splicing influence the physiology of the lactating animal.
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Figure 5.1: Workflow for detection of differential alternative splicing. Data are
initially imported and saved as gene level, probeset level (exon level), and/or at
the level of individual probes, depending on the summarization method used.
From here, data that would likely contribute to false positives are filtered out.
Following the filtering algorithm, various methods can be applied to analyze the
datasets, calling up filtered data at the appropriate summarization levels (gene,
probeset, or probe) as input. Venn diagrams can be used to compare results
across the various methods by cross-referencing which genes, and in some
cases exons, test positive by the various tests.
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Appendix A: List of Abbreviations
Prl-Prolactin
Abc-Adenosine Triphosphate Binding Cassette
Thra- Thyroid receptor alpha
Thrb-Thyroid receptor beta
Klf9-Kruppel like factor 9
TRα1-Thyroid receptor alpha isoform 1
TRβ1-Thryroid receptor beta isoform 1
T3-triiodothyrodine
PI3K-phosphoinositide 3 kinase
AKT- v-akt murine thymoma viral oncogene homolog
PIP2-Phosphotidyl inositol 4,5 bisphosphate
PTEN-Phosphotase and tensin homolog
PDK1-Pyruvate dehydrogenase kinase 1
FOXO-Forkhead box transcription factor
mTOR- Mechanistic target of rapamycin
4EBP1-Eukaryotic initiation factor 4E binding protein 1
PEPCK-Phosphoenolpyruvate carboxykinase
G6P-Glucose 6 Phosphotase
AMPK-Adenosine monophophate kinase
Hmgcr-3-Hydroxy-3-methylglutaryl Coenzyme A reductase
Glut4- Glucose transporter 4
Acc-Acetyl-Coa Carboxylase
CRTC2-CREB regulated transcription coactivator 2
SREBP-Sterol regulatory element binding protein
Ppargc1α-Ppar gamma coactivator 1α
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JAK-Janus Kinase
STAT-Signal transducer and activator of transcription
Prlr-Prolactin receptor
SR-Serine arginine
Slc-Solute carrier
Cyp-Cytochrome P450
Erk-Extracellular signal related kinase
Asbt- Apical sodium dependent bile acid transporter
Ntcp- Sodium taurocholate cotransporting polypeptide
Srebf- Sterol regulatory element binding factor
Scap-SREBP chaperone
Ugt- UDP glucuronosyltransferase
DNA-Deoxyribonucleic acid
RNA-Ribonucleic Acid
RMA-Robust multichip averaging
ANOVA-Analysis of variance
FWER-Family wise error rate
FDR-False Discovery Rate
PFP-Proportion of false positives
DAVID-Database for annotation visualization and integrated discovery
EST-Expressed sequence tag
MiDAS-Microarray detection of alternative splicing
FIRMA-Finding isoforms through robust multichip averaging
ANOSVA-Analysis of splicing variance
DABG-Detection above background
Ace2-Angiotensin converting enzyme 2
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Ostα/β-Organic solute transporter alpha/beta
Bsep-Bile salt export pump
FGF-Fibroblast growth factor
Fgfr-Fibroblast growth factor receptor
RT-PCR-Reverse transcriptase polymerase chain reaction
Rg9-mtd2- RNA guanine-9 methyltransferase domain containing 2
KEGG-Kyoto Encyclopedia of genes and genomes
Ch25h-Cholesterol-25 hydrolase
Akr1d1-Aldo keto reducatase family 1 member d1
Acox2-Acetyl-CoA oxidase 2
Scp2-Sterol carrier protein 2
Baat-Bile acid-CoA:amino acid N-acyltransferase
IPA-Ingenuity Pathways Analysis
CD28-Cluster of differentiation 28
IL-2- Interleukin 2
Insig-Insulin induced gene
Scd2-Stearoyl-Coenzyme A desaturase 2
ME1- Malic enzyme 1
Ctsb-Cathepsin B
Tmbim6-Transmembrane BAX inhibitor motif containing 6
Tmed2-Transmembrane emp24 domain trafficking protein 2
Tmem97-Transmembrane protein 97
NPC1l1-Niemann Pick 1 like 1
Fdft1-Farnesyl-diphosphate farnesyl transferase 1
Mvk-Mevalonate Kinase
Pmvk-Phosphomevalonate kinase
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Mvd-Mevalonate decarboxylase
Idi1-Isopentyl-diphosphate delta isomerase 1
Sqle-Squalene epoxidase
Lss-Lanosterol synthase
Dhcr7-7-dehydro cholesterol reductasse
BLAT-BLAST like alignment tool
UCSC-University of California, Santa Cruz
Anpep-Alanyl aminopeptidase
Lnpep-Leucyl/cystinyl peptidase
Mme-Membrane metallo-endopeptidase
Ahr-Aromatic hydrocarbon recptor
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